weiver raey roche face weather challenge nearly year solidarity community experience fight covid significantly increase collaboration doubt come strong severin schwan ceo roche group video roche strongercontent reliable partner management perspective report strategy support patient business review corporate governance remuneration report strdoe patient need strongertogetherwe believe urgent deliver medical solution right develop innovation future passionate transform patient live courageous decision action believe good business mean well world come work day commit scientific rigour unassailable ethic access medical innovation today build well tomorrow proud work function company world rocherentrap elbailer anoroc eht gnirud cimednapa reliable partner roche report begin appear somewhat quietly early soon alarm begin re loudly virus call sarscov suddenly dominate headline threaten life world roche quickly realise company new mission substantial list vital undertaking list include develop new diagnostic tool determine exist medicine combat infection ease symptom develop entirely new medicine treat virus join force government business partner organisation accelerate progress secure employee safety maintain business continuity ensure supply test medicine reach patient need nikki student university california berkeley recover covid enjoy life spend time favourite outdoor activity nikkis storya reliable partner roche close home nearly year ago roche employee michaela receive positive result nikki consult hart daughter nikki diagnose doctor telemedicine travel healthcare significant illness march nikkis worker come check vital administer late hospital visit treatment treatment include intravenous fluid new different way partially open apartment door nikki main concern michaela say infect friday explain michaela vice president quality system compliance take charge healthcare give roche diagnostic pleasanton california nikki sense control michaela say involve start feel sick discharge medical sleuth give way hospital own diagnosis important result ongoing treatment point patient underlie illness repeat face new possibility covid episode severe dehydration nikki recovery long journey handle nikki sick continue strike michaela daughter strength education university california berkeley trust roche familyboth family move home hope patient daughter employee nikki soon return school keep nikkis mindset positive strong offcampus apartment goal michaela say normal possible hope well career michaela remain focused champion quality start feel sick consider voice perspective usual way michaela explain hard customer patient daily workplace say covid decision moment michaela say well selfisolate apartment realise time customer sick care daughter close home nikki return apartment soon sicker high fever doctor recommend test covid involved test come negative nikki unconvinced say mother know covid medical sleuth give way flu feel different different virus own diagnosis nikki insist covid test important patient week wait phone call future hinge partnership look experience covid development goal experience painful alain bindel head innovation realise importance solidarity facilitation digitalisation roche explain sustainability building ecosystem tough moment life feel change happen helpless realise fragile life week know outcome opportunity harness solidarity well able globe family disease transform alain annual innovation summit organise recover alain say observed creativity agility spur man virus days pandemic recognise opportunity harness fever high degree celsius solidarity globe alain see power loss oxygen blood stumble unite innovator pharma government bed word everpresent mind academia startup nonprofit individual solidarity work deliver solution matter patient registration miss connection clear external company join include company covid alain begin connection euvsvirus hackathon roche world miss sponsor partner find solution covid realise importance sustainability society community individual alain wish future build firmly believe futurepersonally ecosystem partnership startup university professionallyhinge partnership expert private company ngo patient centre alain think way forward covid say focus determine collaboration help bring world function alain say honest sick ecosystem centre patient need focus sustainability sustainable life fragile ask surprised experience covid patient alain say fragility life connection pandemic demonstrate vulnerability allow big community big world benefit unite innovator care say think life fragile society fragile want create pharma government academia positive future sustainable future everybody need rethink work society startup nonprofit individual community personal levela reliable partner roche alain head innovation facilitation digitalisation roche state person contract sarscov infection word everpresent mind solidarity alain story support high demand sarscov testing increase production capacity unparalleled level allocation strategy ensure test consumable system available need effective thomas schinecker ceo roche diagnosticsa reliable partner roche research novel coronavirus urgent search solution human history pandemic end quarter roche afflict world fact inevitable pcr diagnostic test identify active infection life earth global challenge approve launch record time covid bad modern history global scale combat virus demand modern approach join force unprecedented solidarity urgency quick start april multinational group consist complete genome sequence sarscov global health regulatory agency determine public january dozen lead biotech company immediately initial outbreak renowne academic researcher band virus genome sequence follow quickly battle disease know border world collaboration call accelerate covid therapeutic intervention vaccine activ sequence availability provide vital blueprint develop new test diagnose virus drug effort lead national institutes health fight nih foundation nih public private partnership truly pandemic proportion summon resource bring wide range expert include early pandemic roche initiate internal industry leader director nih research programme develop sarscov director national institute allergy tests discover potential drug combat infectious disease health human service virus roche establish internal office assistant secretary preparedness review team rapidly evaluate large number response center disease control potential partnering opportunity determine prevention food drug administration complement expertise hold fda european medicine agency ema promise roche provide support external collaborator include krogan lab global challenge covid university california san francisco identify possible new therapeutic approach exist bad modern history fdaapprove medicine collaboration calibr scripps research involve roche combat virus demand provide discovery stage compound screen potential antiviral activity modern approach sarscov april entire activ group gather addition roche enter private weekly basis virtual room share public partnership barda advance align develop coordinated global response development medicine infectious disease goal activ straightforward prioritise significant unmet need good vaccine drug candidate streamline agreement barda provide fund clinical trial regulatory process share support development baloxavir knowledge tool partner order marboxil severely ill hospitalise influenza respond covidand future pandemic patient potential funding quickly possible study key aspect approach willingness safeguard ongoing clinical studiesand people industry academia government participant private foundation work march steep rise sarscov infection difference effort strive break begin capture great deal attention traditional boundary silos normally slow resource roche time company progress openness transparency collaboration take significant measure ensure ongoing share goal address global health clinical study condition continue crisis important attribute uninterrupted study participant unprecedented collaboration especially cancer trial advance stage disease roche go roche evaluate safety efficacy great length ensure protect actemraroactemra hospitalise adult patient possible severe covid pneumonia effort collaboration biomedical advanced study team ask flexible research development authority barda empower step necessary department health human protect patient approach unusual service collaboration time effective function team roche combine force barda developed multiple way protect patient roche enter multiyear publicprivate disrupt study method partnership federal authority effort adjust meet specific need jointly combat rise antibiotic resistance level individual patient requirement development new antibacterial drug result plan pivotal trial start filing pointofcare diagnostic drug launch remain largely tracka reliable partner roche covid change way thing lot positive way give huge sense purpose mission actually science william pao head roche pharma research early development predthe ongoing complexity covid require multiple line defence join force company hope offer additional treatment option hospitalise nonhospitalised covid patient ease burden hospital global pandemic bill anderson ceo roche pharmaceuticalsa reliable partner roche partnershipsbuilt combine strength develop anticovid medicine partnership agreement clear example people globe continue struggle amazing thing accomplish covid pandemic effort align common vision clear solution need quickly patient centre early roche focus relentlessly possible help people community impact covid effort global partner innovative drug discovery partnership regeneron collaborate platform technology development manufacturing distribution work stakeholder investigational covid antibody combination crucial combat covid pandemic casirivimab imdevimab vital fight noncovidrelate disease spite pandemic succeed antibody combination currently adaptive establish new partnership focus study target specifically sarscov develop late scientific innovation consist noncompete virusneutralise bring patient multiple collaboration antibodie casirivimab imdevimab agreement support effort increasing administer bind critical efficiency drug discovery different receptorbinde domain viruss spike protein therapeutic area diminish risk viral escape key partnership example include initial datum ongoing study show reduction viral load decrease medically attend blueprint medicinesroche visit non hospitalise patient covid licence collaboration agreement new november fda grant emergency personalise treatment gavreto pralsetinib use authorization eua casirivimab patient retaltere nonsmall cell lung imdevimab cancer nsclc medullary thyroid carcinoma type thyroid cancer solid tumour lead biotech manufacturer roche place help bring new therapy patient global regeneron partnership commit significant manufacturing capacity work expand supply partnership agreement antibody combination people possible clear example amazing thing october partnership atea pharmaceutical accomplish effort inc announce develop manufacture distribute ateas investigational oral direct align common mission act antiviral people globe reverie labsrochegenentech vividionroche multitarget collaboration agreement utilise collaboration licence agreement develop artificial intelligence drug discovery smallmolecule medicine difficulttodrug reverie machine learn platform promise intracellular target vividion proprietary drug augment accelerate drug discovery discovery platform help address range increase power predictive algorithm target interest pre oncology relevant smallmolecule property pre immunology roche provide bind gre leverage platform ligand define target nominate smallmolecule kinase program support collaboration roche aim deliver twice medical advance society half cost addition new drug discovery technology roche enter multiple new partnership arrakisroche range different therapeutic area collaboration licence agreement develop modality include rnatargete small molecule disease area arrakis developed pioneer bicycle therapeuticsgenentech drug discovery platform integrate rna collaboration agreement discover develop bioinformatics structural tool commercialise novel bicycle therapeutic base comprehensive proprietary screening process immunooncology therapy platform identify small molecule impact broad set target pred forgeroche disease area arrakis lead initial research collaboration identify develop novel activity roche conduct antibiotic treat lung infection commercialisation attribute antibioticresistant gramnegative bacteria samsung harman internationalroche collaboration research agreement develop digital therapeutic platform autism digital health product ucbgenentech development commercialisation agreement develop manufacture commercialise ucb middomain antitau antibody treatment alzheimer disease collaboration agreement inflazomeroche support effort increase acquisition oral smallmolecule inhibitor nlrp complement roche exist efficiency drug discovery immunology neuroscience portfolio provide potential addon combination multiple therapeutic area product developmenta reliable partner roche obvious work stakeholder crucial combat covid pandemic ensure slow innovation disease area james sabry global head pharma partnering thank hard work dedicate staff roche deliver high doubledigit million test month sarscov diagnosisa reliable partner roche safeguarding operation scientist roche continue work reagent consumable sarscov testing tirelessly year develop laboratory use magna pure entire portfolio test solution help lightcycler system course year fight pandemic production output pcr test increase fourfold step patient swift development sarscov diagnostic solution pcr test soon follow launch roche diagnostic manufacturing elecsys antisarscov antibody test distribution site rapid response team receive fda eua serology work clock produce deliver test design help accurately assess prior commercial test detect novel coronavirus infection sarscov determine patient develop antibody march pcrbase cobas sarscov virus information essential epidemiologic test receive fda eua study ongoing surveillance vaccine study comprehensive portfolio solution quickly begin ship new antibody test help combat pandemic hour lead laboratory globally ramp receive authorisation fda production capacity high doubledigit million manufacturing team branchburg new jersey month serve healthcare system send test kit door colleague country accept mark hospital indianapoli distribution centre begin shipment reference laboratory run test day later roche cobas analyser widely available world zero million record time tremendous personal commitment effort crossfunctional collaboration possible develop produce distribute test week approval million test deliver globally accordance allocation strategy provide test need roche diagnostic site effective emergency response team work provide million test month highthroughput cobas system clock develop produce roche molecular system team branchburg work clock multiple task force deliver diagnostic test create maximise production capacity maintain health safety manufacturing combat pandemic personnel addition continue supply scale production medicine meet ask conduct intercompany demand technology transferthe precise process produce biologic complicated time transfer skill knowledge technology consume good circumstance method produce specific product process persuade live cell produce process roche manufacturing site biological medicine exact highly technical transfer take incredible biologic base large complex planning attention detail close coordination protein produce cell cell ensure production transfer live need careful tend site alignment rigorous sterile environment constant monitoring parameter control quality system strict documentation government regulatory approval vital regulatory rule make sure medicine available patient march country move lockdown response everwidene pandemic technology transfer normally take time roche expert team world month hillsboro team complete ramp goal supply need process week compromise medicine rely make quality safety secret quick medicine possible nimble give team clear focus define need later goal power decision early march request come team product plane day genentech fill finish facility hillsboro manufacture precise transportation oregon liquid biologic medicine schedule crucial early transfer transfer large batch small vial process team quickly discover label packed prepare shipping flight available medicine globe destination world roche supply chain expert help team track target flight need meet demand tight schedule undertaking like typically take day production planning releasing shipping hillsboro team complete team complete complex task job day week instead month despite lockdown social distancing uncertainty home schooling challenge compromise quality team work nonstop shift seven day week midmarch july finally july safety holiday take short break technology transfera reliable partner roche reward month career proud achievement impact patient society hillsboro employee work nonstop shift seven day week midmarch july course pandemic roche production logistic team repeatedly prove expertise excellence deep commitment serve patient worldwidea reliable partner roche tirelessly tenaciously keep system run work home curb spread manufacture logistic team coronavirus roche site world continue operate uninterrupted roche organisation clock work tirelessly tenaciously manufacture logistic team continued produce ship organisation continue produce ship urgently need medicine test medicine test people everyday hero roche understand importance work know need urgently important pandemic fully realise gravity mission patient cancer autoimmune disease heart disease rare condition depend treatment agility crucial example include threeyear pandemic present supply old child haemophilia risk logistic challenge thank resilience run vital hemlibra supply global network disruption lockdown medicine deliver minimal roche continue deliver crucial regular coldchain logistic company test lifesave medicine patient local roche team take action review range world roche work urgently accelerate possible solution find way ensure manufacturing capacity order maximise family receive medicine time production critical test medicine treatment continue uninterrupted goal increase available supply globally illustrative example come roche commit deliver combine effort highly motivate team coronavirus test possible area roche pharma basel roche hub singapore need test ship roche diabetes care thank work roche production site location unit medication medical appropriate infrastructure place testing product load joint oneroche begin delay charter flight deliver myanmar lockdown accessible commercial roche work ensure coordinated global flight road special solution help overview additional supply request provision save life provide medication patient need medicine manage country level include tecentriq kadcyla herceptin accordance local rule regulation accuchek roche diabete care close collaboration local authority pandemic spread globe research operational level finance perform roche finance organisation keep watch task successfully trial run entire enterprise provide expertise need success technology automation navigate uncertainty company importantly expertise experience course unprecedented collaboration teamwork affiliate headquarters service team time heighten need finance team provide insight transparency record procurement team partner closely speed support unfold strategic dialogue supplier work wonder accelerate decisionmake organisation contracting help set covidrelated strategic guidance keep funding flow help actemraroactemra trial day protect business continuity ensure minimal opposed month source material impact pipeline able ensure business continuity procure time invest confidence longterm critical blood sample essential scientist develop covid antibody assay million personal protective equipment item include surgical face mask source deliver organisation include agile flexible way work supplier company need spirit procurement provide supplier demonstrate covid financing make establish newly develop financial solution available partner pandemic procurement company day agile flexible way work demonstrate covid new normal pandemic procurement new normala reliable partner roche like healthcare worker respond covid struggle balance work need need family exhausted proud able release test going country world test million people pleasanton employee roche molecular system california country recognise lot effort regulatory improve access covidrelated product domestic consumption export support economy harjit gilla reliable partner roche technology critical factor contain outbreak world fight pandemic harjit gill ceo scrambling manage outbreak asia pacific medical technology association medical technology industry double apacme share lesson learn far effort ramp production explain role regulator prepare region challenge future harjit gill describe step government asiapacific take streamline regulatory social distancing selfisolation flattening process ensure availability important curve slowly find way everyday resource fight grow pandemic conversation prepare include accelerate approval medical world pandemic face product personal protective equipment strain collective resource way diagnostic test kit enable euas life explain harjit gill diagnostic unapproved product approve alternative core sustainable healthcare role available critical contain outbreak help identify infected patient early testing take advantage digital technology prevent communitywide transmission healthcare ensure access timely treatment race see public private sector ramp bring muchneede equipment testing technology adoption digital technology treatment countrie health authority telehealth case track contact trace work clock ensure regulation aiassiste diagnosis software remote training meet need constantly change push wide deep utilisation environment digital technology entire ecosystem well prepare crisis sudden emergence rapid transmission state harjit gill covid devolved global health crisis current healthcare system face highly infectious nature novel coronavirus lead country take drastic action prevent widespread transmission emergence severe diagnostic core acute respiratory syndrome sar middle east respiratory syndrome mer recently sustainable healthcare role ebola highlight gap plague healthcare system outbreak reach pandemic critical contain level twothird world healthcare system illprepare pandemic accord outbreak global health security index report hospital httpswwwghsindexorgwpcontentuploadsglobalhealthsecurityindexpdf utilise telemedicine safely help patient technology medicine pharmaceutical safety add artificial intelligence algorithm powerful important slide image analysis offer potential example demonstrate roche utilise bring important new information pathologist new technology help patient safely profoundly impact patient tool replace pathologiststhey enable digital pathology serve patient efficient confident diagnose clinician spread covid add new challenge precise diagnostic lead effective element actual physical danger treatment practice pathology physician new tissue test cancer require high staff high risk exposure virus level quantitation determine specific site hospital laboratory digital subtype cancer patient pathology enable remote diagnosis qualifie target therapy assay emerge vital technology depend tumour immunecell count precise estimate tumour area roche offer comprehensive solution case combination biomarker support pathologist transition slideor multiplex assaysgive pathologist digital era technology enable ability pinpoint molecular driver pathologist collaborate cancer raise confidence select world prime important contribution good treatment plan patient complex telehealth future assay difficult interpret manually benefit greatly image analysis algorithm ability diagnose patient location support evaluation pathologist particularly crucial global pandemic digitising glass slide powerful lung cancer provide helpful example slide scanner integrating result past treatment option workflow tool like upath enterprise software patient disease today collaboration significantly boost efficiency therapy treat disease important patient precise diagnosis new tool technologiesinclude ceivd upath pdl image analysis algorithm nsclcaid medical team determine effective treatment patient base standardised precise consistent ability diagnose patient method endtoend solution slide scan digital workflow automate location particularly critical image analysis roche digital pathology provide complete solution healthcare provider benefit global pandemic transition digital eraa reliable partner roche people underlying disease face high risk severe illness course covid reduce risk social distancing telemedicine important factor avoid infection maintain access medical counselling care bring true relief integrate personalised diabetes management enable open ecosystem assess need structure therapyadapte datum monitoring assess effectiveness structure documentation personalise treatment collaborative reviewa reliable partner roche diabete care change significantly covid pandemic boost adoption digital technology vital seamlessly connect people diabete healthcare professional people diabete similar risk contract covid general population infected face high risk people diabete outside conventional severe illness maintain blood glucose level health checkup therapeutic target rangeboth short longtermis crucial reduce likelihood effort expand selfsupport capability covid disease background people diabete worldwide roche decide social distancing limit access healthcare early covid pandemic provide free pose additional challenge nearly half access pro version patientface mysugr billion people live diabetes worldwide app app enable patient share datum healthcare professionalswhich diabete demand constant monitoring important time patient spend patient numerous treatment decision significantly time physician day diet exercise medication decision app integral open ecosystem patient ideally close coordination offer feature like structured log physician covid pandemic documentation therapyrelevant datum accurate diabetes care change significantly insulin dose calculation reminder engage boost adoption digital technology challenge coach help people well essential roche able facilitate shift manage daily diabete routine strategy integrate personalised diabetes management ipdm recent year roche december roche announce partnership develop open ecosystem diabetes care diabeloop french medtech company enable meaningful interaction partnership roche enter people diabete physician field automate insulin delivery help advance management insulin pump therapy january roche launch accuchek insight insulin pump roche rochediabetes care platform key component pump automatically dose insulin base open ecosystem utilise healthcare reading continuous glucose monitor professional integrate datum lower burden people diabetes device solution roche partner daily therapy management sharing diabete competitor platform design relevant datum integrate solution contextualise datum point smart algorithm prove especially beneficial time face provide actionable insight toface visit limit remote consultation personalise approach diabetes care preferred method ensure additional solution platform introduce uninterrupted support systematic include rochediabete approach ipdm centre physicianpatient insulinstart service enable easy transition interaction roche strengthen connection insulin therapy people type diabetes patient care team help rochediabete remotecare solution people diabetes confidentially manage allow healthcare professional monitor condition covid pandemic new option patient disease covid dominate public discussion estimate woman globally die year people combat disease disease nearly preventable roche continue research development proper screening vaccination treatment activity multiple disease area include roche focus science hpv know oncology immunology infectious disease cause case cervical cancer help ophthalmology neuroscience provide answer aid clinical decisionmake patient care new therapy spinal muscular atrophy allie yearold live spinal muscular advanced objective pki biomarker technology atrophy sma type treatment nextgeneration triage solution woman youtube channel chronicle test positive highrisk hpv technology journey lead receive evrysdi story offer significant improvement risk stratification include fda approval evrysdi learn compare traditional pap cytology impact doctor approve receive improve primary screening colposcopy triage treatment culminate heartwarme video trial nearly woman landmark cervical take dose experience go cancer screening study support multiple fda forward video show caregiver assist approval receive include cintec administering evrysdi allie noting plus cytology cobas hpv use cobas treatment big deal hopeful system cobas hpv test identify thankful scientific advancement woman risk cervical cancer detecting allow stay alive long live presence highrisk hpv dna cervical sample additionally cintec plus cytology hpv testing prevent cervical cancer triage test base dualstain technology roche significant stride women biomarker identify woman health improvement cervical cancer risk benefit immediate screening triage diagnostic testing followup cintec histology biomarker test cervical biopsy provide clear diagnostic confirmation cervical lesion hpv innovation advance goal eliminate cervical cancer estimate patient perspective come woman globally die year roche employee patient caregiver personal life deal cervical cancer nearly illnesse type covid breast cancer diabete disease central nervous preventable proper screening system experience gain expertise area vaccination treatment regular work responsibilitiesa reliable partner roche approval medicine rare disease meaningful difference people living condition support physician treat exemplify patient industry academia authority find solution eva joseph look microscope cancer tissue section glass slide slide explain eric walk chief medical officer roche tissue diagnostic tucson arizona site visit november triple negative breast cancera reliable partner roche covid dominate public discussion people combat disease enable people possible benefit substantial experience expertise carering establish internal community herneuare express tumour making provide framework roche employee share difficult treat experience support reassure colleague fight disease fortunately evas oncologist tell new carering effective way support clinical study chance survival quickly commitment put patient centre formidable team roche cancer effort programme employee immunotherapy medicine roche diagnostic share insight experience roche test powerful collaboration business team early product development diagnostic pharmaceutical team process carering member help inform deliver market bring new hope strategy discussion communication effort eva patient diagnosis include covid pandemic amazing say eva tumour nearly vanish feel blessing able year employee receive treatment world join carere member active group dedicated expansive range health issue carere result quick promising eva recognise reuters pharma awards europe explain round treatment begin promise mvppilot award feel strong scan show celebrates carering potential disrupt tumour lung sternum shrink status quo allow contact real patient treatment early stage project activity typically take week submit test treatment fda approval diagnostic team come cut time submission half retire business woman eva joseph important test base study fda survive breast cancer nearly year approve roche test treatment follow ago returnedwith vengeance eva soon country make test receive diagnosis triplenegative breast cancer therapy combination approve triplenegative learn spread lung sternum breast cancer globally remarkable partnership believe certain death sentence roche pharmaceutical diagnostic terrify eva recall learning division lead well care patient like eva face highly aggressive disease poor passionate spread word prognosis thought dead week new testing treatment option eva know survive stage cancer husband dwight rally support cancer research funding year people diagnose triplenegative breast cancer worldwide want tell help diagnosis mean common hope eva say help protein associate breast cancer growth information give hope people like oestrogen receptor progesterone receptor triplenegative breast cancer hopetnemeganam sevitcepsrepmanagement perspective roche strong focus collaboration share knowledge lockdown measure introduce globe mean roche find smart new way ensure continue research produce medicine diagnostic test interruption work partner supply chain move hoffmann bbuullcckkee dduusscchhmmaall frost hauser lifton poussot clevers brown schwan franz suessmuth dyckerhoff roche board director december christoph franz chairman andr hoffmann vicechairman representative shareholder group pool voting right paul bulcke jrg duschmal representative shareholder group pool voting right patrick frost anita hauser prof richard lifton bernard poussot prof hans clevers julie brown severin schwan claudia suessmuth dyckerhoff corporate governance sustainability committee audit committee remuneration committee chairmansnomination committee nonexecutive director executive director independent member board director committee chairpersonchairman shareholder letter roche dear shareholder coronavirus pandemic dominate efficacy patient severely affect world affair like event recent history covid launch new research place tremendous demand ussome project work partnership excessive reason roche levelsinclude pharmaceutical grateful frontline effort industrymore intensively overcome pandemic particular develop time crisis particular solidarity extremely reliable diagnostic test record time cooperation key success andthank close trusting relationship interview ceo severin schwan government authoritieshave able deploy offer great benefit covid crisis lead few patient see doctor routine checkup proud start new therapy employee world important cancer treatment face accomplish difficult situation competition biosimilar usa despite give utmost deal competition ongoing strong demand covid new medicine tecentriq cancer immunotherapy power ensure patient reliable hemlibra haemophilia ocrevus multiple supply medicine diagnostic test sclerosis new molecular test lead condition type disease slight sale increase chf billion simply disappear new virus ifrs net income increase swiss emerge roche employee ensure franc chf billion mainly lower vital continuity persist despite shortage goodwill writeoff compare previous transport capacity difficulty associate year view positive overall result consult doctor outstanding prospect propose dividend increase chf share value strong infrastructure diagnostic subject approval increase substantially pandemic consecutive dividend increase broad access molecular diagnostic test essential control new recur infectious major reason confidence disease test help prevent impressive progress product condition cervical cancer pipeline year grant authorisation liver cancer hepatitis stateoftheart new medicine record diagnostic early identification prevention number new compound registrational possible grow number disease study file approval turn help improve health outcome boost costeffectiveness healthcare system like mention newly approve medicine treat rare disease evrysdi pharmaceutical work closely hereditary sma disease cause muscle health authority test medicine weakness enspryng major milestone state growth rate report constant exchange rate cer average treatment genetic disorder increase record level research nerve cell attack bodys development spending immune system like thank employee rest assure covid crisis pass exceptional commitment challenge time plenty illness partner greatly value cooperation roche continue combat nearly dear shareholder confidence year found roche repeatedly loyalty company reinvent order seize opportunity help people thank proactive commitment digitalisation company excellent shape future position achieve medical breakthroughswell coronavirusthrough outstanding scientific christoph franz performance end chairman board directors christoph franz visit roche diagnostic penzberg germany conversation employee inform site challenge contribution production logistic connection sarscov testschairmans shareholder letter roche proud employee difficult situation thing clear lifethreatening disease simply disappear new virus christoph franz chairman board directors schwan anderson schinecker hippe wilbur regev pao sabry schdler bckstiegel roche corporate executive committee december severin schwan ceo roche group bill anderson ceo roche pharmaceutical thomas schinecker ceo roche diagnostic alan hippe chief financial information officer cristina wilbur chief people officer aviv regev head genentech research early development gre william pao head roche pharma research early development pre james sabry global head pharma partner barbara schdler head group communications claudia bckstiegel general counsel member enlarge corporate executive committeeinterview ceo roche group roche severin schwan coronavirus pandemic partnership suddenly important surprise industry competitor yes like lot people surprise work help fight covid pandemic grow scale company work jointly university overnight pandemic hardly new research centre new roche regard phenomenon mean live pioneer field demand difficult time coronavirus partner new global pandemic eitherunfortunately scale activity development datum sharing production see roche fare like hugely impressed way people respond crisis develop happen join test record time get production run force sudden team work clock urgency find medical solution addition huge commitment see realisation emerge crisis farreache change way work significantly fast work agile courageous example effective decentralise global production capacity antibody treatment decisionmake structure covid extremely limited time key act quickly build roche world lead biotech company step partner agile courageouswhat regeneron produce antibody treatment mean available patient worldwide let example increase individual responsibility concern apart research development year workforce share production roche easier say partnership large complex organisation roche pretty actually achieve work example work beat coronavirus comes give people world access speed process day hear medicine diagnostic make sure case people simply take coronavirus test end initiative act idea wait urgently need particularly important issue green light kind thing enormous challenge small startup company think overcome fantastic completely change way work external partner change go climate change roche go last want reduce environmental impact half decade look new way work product environmental footprint stage partner outside company value creation supply chain knowledge share area work closely quickly transparently include communication business partner point regulatory authority obviously delighted month year take week day eleventh timebeen rank world sustainable healthcare company hope speed trust continue dow jones sustainability indices postcoronavirus era million people benefit covid turning world upside discover wide range antibiotic mean fight disposal thing use disease antibiotic resistance lose sparingly especially true momentum somewhat like recent reserve antibiotic yes unfortunately thing world exist antibiotic work learn pandemic simple reason few reserve antibiotic prepare save people lives use low risk bacteria costefficient long term resistant quantity sell reserve antibiotic small antibioticresistant bacteria claim need reflect reimbursement live year number rise investment research major threat far little development worthwhile company work infectious disease point pandemic end financial incentive virtually consequence roche nonexistent change pandemic throw value diagnostic digitalisation sharp relief diagnostic exactly need change boost continue systematically antibiotic revolutionise thcentury expand digital healthcare business medicine today century penicillin future roche group future healthcare lie let assume minute future reality different imagine treatment recent live projection building basel roche express month datum obtain big thank help systematically log computer imagine covid crisis able continuously evaluate analyse immense treasure trove datain anonymised form course able well view patient respond treatment short time research development medicine covid substantially advanced stage regard realworld datapatient data routine clinical practicea big topic medicine datum hugely valuable covid disease big personal takeaway pandemic lockdown give time reflect thing truly important life family friend health course solidarity challenging time crisis show need otherand strong togetherinterview ceo roche group roche impress way employee manage crisis agile courageous severin schwan ceo roche group time initial outbreak pandemic little know new coronavirus patient need deliver disease cause grateful colleague world step fight innovative medicine pandemic ensure continuity patient care disease area address medical multiple disease area question implication covid call deliver bill anderson ceo roche pharmaceutical innovative medicine multiple disease area overcome unprecedented supply chain logistic hurdle help meet demand pandemic experience remind crucial role robust clinical trial help answer pertinent scientific question demonstrate importance reliable health system encourage party healthcare continuum work great speed efficiency collaboration prove care compassion lockdown lifecorporate executive committee roche provide million covid pandemic clearly demonstrate value importance diagnostic test month help fight forefront fight global healthcare crisis pandemic reduce record time develop comprehensive burden healthcare system testing portfolio new viral disease significantly ramp manufacturing capacity provide million test month help fight pandemic reduce thomas schinecker ceo roche diagnostic burden healthcare system time able continue make substantial contribution healthcare new test solution cancer hiv womens health exceptional challenge demand exceptional response intensely proud commitment resilience demonstrate organisation agile open collaborative mindset help continue address challenge healthcare face right patient customer finance procurement pandemic spread globe finance procurement colleague provide expertise helped navigate expertise need navigate uncertainty company course roche finance uncertainty provide insight transparency record speed enable funding flow protect company course business continuity uphold ability invest confidence longterm research alan hippe chief financial information officer procurement colleague partner closely supplier businesscritical issue include accelerate contracting covid relate actemraroactemra trial procure timecritical blood sample essential develop covid antibody assay organisation keep business system run people connect covid hit employee globe shift remote working overnight fare thank cloud platformasaservice strategy forwardthinke focus investment infrastructure dedicate people world incredibly grateful immensely proud groupscorporate executive committee roche shift agile way sense accelerate pace unpredictable nature change begin work prove especially consciously shift agile way work year ago effective year like key aspect transition embrace mindset look situation challenge opportunity add value patient cris wilbur chief people officer stakeholder mindset place leader enable people connect work selfsufficient creative networked way drive capability outcome hierarchy establish paradigm new approach prove especially effective year like predict dramatically pandemic impact live response colleague roche impressive demonstrate able seemingly impossible possible inspire incredibly proud people special culture deep commitment purpose launch trial join genentech research early development august clear focus covid pneumonia matter colleague fight pandemic learning week month covid different phase different treatment appropriate gred embark early development therapeutic aviv regev head genentech research help covid patient launch early development gre trial study impact medicine covid pneumonia trial launch matter week typical monthswithout compromise scientific rigour goal study covastil trial potentially prevent progression tissue damage lung covid infection help patient lung tissue damage recover quickly thrilled continue transformative scientific effort seriously ill patient collaboration great colleague partnerscorporate executive committee roche focus maintain addition ensure health safety pre early research momentum possible development focus protect live patient trial maintain discovery clinical momentum possible discovery clinical portfolio continue bring external portfolio opportunity ensure ethical treatment animal prioritise combat covid expert william pao head roche pharma research pre lead join key international early development pre collaboration industry academia internally support actemraroactemra trial andor scientific evaluation external opportunity regeneron collaboration agreement pre team pitch help roche diagnostic accelerate launch timeline covid test share desperately need lab supply local hospital enable patient local community receive actemraroactemra proud grateful pred employee go time patient humankind need emerge obvious work stakeholder pandemic convince crucial combating pandemic like covid ensure slow innovation establish close disease area connection stakeholder work partner scientist organisation enter exciting industry new collaboration sign global pandemic fight covid collaborate closely consortia james sabry global head pharma partnering authority share broad expertise goal accelerate development potential treatment addition new partnership gilead regeneron atea pharmaceutical allow develop manufacture distribute molecule potentially treat prevent sarscov infection emerge pandemic convince establish close connection stakeholder industry enable bring forward good new treatment patient futurecorporate executive committee roche thing particularly reflect strike sheer intensity relentless nature glad passion transformative volatile time covid pandemic impact travel roche employee pursue business daily interaction human being mission ensure business continuity communication heavily engage stay global change pandemic situation order enable smooth transition barbara schdler head group communication lockdown facilitate communication activity launch sarscov test commencement clinical trial company milestone thing particularly glad passion roche employee pursue mission deliver well healthcare patient reach community offer help year extreme solidarity critical factor retain validate trust place patient partner wide world truly strongertogether concern take general counsel switzerland go lockdown attention inevitably employee safe focused legal support company effort maintain business continuity healthy ensure business roche concern continuity employee safe healthy work home onsite businesscritical function ensure uninterrupted manufacturing claudia bckstiegel general counsel medicine diagnostic team leverage expertise safety health environment ensure continue supply patient muchneede medicine day fortunate pandemic plan place possible prepare potential situation extent crisis require extraordinary commitment people involve wish express deep wholehearte thank team roche employee work hard happencorporate executive committee roche celebrate year roche life core roche day employee partner dedicate bold science innovative diagnostic breakthrough medicine improve life people serve year legacy promise future celebrate going celebrate life lifein beauty complexity moment experience share remember possibility horizon lifetransforme science despair hope celebrate lifedna gnitroper ygetartsreporte strategy roche transparent reporting engage stakeholder focus develop new medicine diagnostic solution core component business approach material topic personalise healthcare report approach roche commit transparent reporting endeavour drive economic social environmental performance diligence financial performance report scope boundary discuss annually corporate executive financial nonfinancial reporting consist committee review board director annual report finance report effectiveness group risk management online report include annual financial process regularly monitor group risk statement consolidated financial statement advisory team overall process review nonfinancial performance indicator cover audit committee board director region division roche group review externally appropriate january december financial risk management embed level report scope define outlined group pharmaceutical diagnostic finance report significant division global function conduct formal change scope compare risk opportunity assessment process year develop response plan gri standard materiality material risk opportunity follow gri global reporting initiative guideline read corporate governance transition gri standard gri guideline disclose critical identify longterm business sustainability impact activity environment society trend associate risk opportunity economy end conduct annual basis integrate exist materiality analysis corporate level group risk management process year emerge conduct second global trend include associate risk opportunitie materiality assessment include expert interview identify internal external source feedback stakeholder result assessment feature base finding corporate sustainability page report committee prioritise select business publish website link sustainability trend trend identify healthcare evolution rise chronic risk management infectious disease risk management policy set roche approach identify analyse manage sustainable development goal report internal external risk support united nations sustainable opportunity consolidated group risk report development goal sdgs sphere cover material risk opportunitie corporate business strategy contribute report arrochecom rochecomarepdf rochecomfbepdf risk management rochecomriskmanagement key performance indicator rochecomperformancereporte strategy roche business sustainability trend number sdgs particularly pleased dedicated goal health sdg healthcare evolution goal closely connect achievement healthcare evolution develop continuum universal health coverage go hand hand care approach include prevention treatment cure well access quality essential medicine offer wide range solution product service diagnostic fit perfectly vision unique opportunity accelerate delivery truly improve save life sdgs integrate patientcentric personalise healthcare integral annual reporting solution example introduce navify symptom tracker offer remote monitor covid example contribution goal symptom develop cloudenable integration list sdg webpage link engine support digital health ecosystem mobile app map material topic feature patient healthcare professional like mysugr app monitor manage diabete smartphone risk opportunity associate new digital health external assurance arena assess manage group risk nonfinancial report verify management process pricewaterhousecoopers pwc independent party pwc focus rise chronic infectious disease materiality determination process design increase rate chronic conditionssuch diabete sustainability risk opportunitie determination cardiovascular diseasesare put lot pressure process figure area safety healthcare system lead rise cost longterm security health environmental protection treatment threaten recent societal gain life people contribution result expectancy quality addition outbreak infectious roche strengthen control framework review disease rise covid pandemic procedure report aspect figure currently experience demonstrate significant social relate grant donation sponsorship economic impact pandemic exacerbate healthcare patient organisation subject need work close collaboration global institution reasonable assurance perform pwc government partner develop new drug figure disclose nonfinancial report innovative product encourage explore new key performance indicator webpage include approach drive urgency example speed pwc assurance report drug development process independent assurance report materiality assessment stakeholder engagement engage stakeholder essential building trust understand expectation embed feedback strategy daily business able jointly address common issue develop longterm solution order identify topic particularly institution peer supplier contract research relevant roche stakeholder society organisation university investor large deliver last share value collect external internal conduct indepth stakeholder view online survey identify corporatelevel materiality assessment important press issue roche key stakeholder assessment build address year materiality analysis conduct add external perspective gain critical insight final step analyse insight important stakeholder identify material topic stand learn consider emerge trend highly relevant key stakeholder topic properly address topic align current goal measure approach performance define set indicator approach materiality assessment integratedbuilde group risk management addition materiality assessment processand inclusive design share internally function charge collaboration colleague multiple manage respective topic assessment function risk advisory human resource inform discussion define investor relation compliance finance safety new corporate goal subsequent sustainability security health environmental protection objective communication priority communication roll finally outcome materiality assessment outcomes group risk integrate group risk management management process start point identify process key emerge trend relevant roche group conduct qualitative interview process result materiality expert broad stakeholder analysis endorse roche category include patient organisation global corporate sustainability committee materiality rochecommateriality key performance indicator rochecomperformance contribution sdgs rochecomunsdgsmateriality roche material topic commit deliver sustainable value stakeholder address follow material topic commitment performance material topic support sdgs innovate patient million patient treat roche sustainable healthcare system commit develop medicine availability healthcare medicine diagnostic billion test conduct roche affordability healthcare significantly improve people live diagnostic product personalise healthcare deliver rapid broad btds breakthrough therapy designation realworld data sustainable patient access award fda patient centricity product roche medicine model list efficiency essential medicine preparedness age society product safety product quality trustworthy partner new partnership pharmaceutical human right commit establish diagnostic ethic transparency mutually beneficial longterm business critical supplier audit compliance relationship partner product safety product quality cybersecurity datum privacy realworld datum provide great workplace key leadership role hold woman talent attraction retention commit provide work employee engagement organisational agility environment employee preparedness age society encourage build career pursue passion protect environment decrease energy consumption energy efficiency commit minimise employee longterm mindset environmental impact operation decrease general waste use product employee deliver continue growth group sale longterm mindset commit create value core operating profit continuously stakeholder sale invest achieve sustainable high profitability growth rate report constant exchange rate cer average strategy focus find new medicine diagnostic establish database insight evolve practice medicine help patient live long well live business environment undergo tremendous exceptionally broad deep understanding change face new challenge disease biology seamless integration complexity care increase pressure capability pharmaceutical diagnostic healthcare budget time new diversity approach maximise innovation opportunity arise major advance life longterm orientation science digitalisation healthcare delivery create value turbulent time guide stakeholder partner choice bring common purpose patient significant medical benefit patient doctor need company bring novel payer offer great place work diagnostic treatment patient nearly employee deliver sustainable positive year patient remain core contribution society earn competitive reason come return investor work day ultimately deliver commitment take focus vision fitting treatment people integrity courage passion patient provide right therapy right make difference patient people patient ensure good response right proud roche time right value approach combine rich expertise pharmaceutical diagnostic leadership inspire outcome matter expand datum science capability drive embrace diversity inclusion different effective efficient research background perspective experience enable well therapeutic decision patient entire organisation foster innovative solution benefit patient way work working partnership party enable agile networked response offer integrate solution improve medical increase pace change balancing need health economic benefit work stability speed flexibility different stakeholder healthcare ecosystem broaden access offering people setup design innovation need ultimately provide seamless autonomous research development centre patient journey continue concentrate alliance external partner energies prescription medicine vitro foster diversity scientific approach agility diagnostic diversify sector global geographical scale reach enable like generic biosimilar overthecounter attract talent lead global science medicine pursuit excellence science cluster quickly bring solution people distinctiveness rest key element need themour strategy roche focus leadership fitting treatment patient inspire outcome matter distinctiveness way work excellence science agile network delivery setup value stakeholder build innovationgnitroppus stneitapsupporte patient roche covid severe disease develop broad portfolio diagnostic solution new medicineswithin roche jointly number partner industry diagnostic solutionsthe backbone treatment decision reliable testing contain spread covid pandemic support development effective safe medicine vaccine response ongoing public health crisis patient infect diagnostic draw strength virus antibodie test global network multiple site ongoing launch partnership biosensor effort increase production sarscov inc south korea roche global portfolio substantial investment distribution agreement build additional manufacturing capacity enable increase production test september roche launch elecsy instrument test antisar cov antibody test market perform accept mark target antibodie spike protein november receive february begin work fda eua test food drug administration fda produce quantitatively measure antibodie people coronavirus test emergency use authorization expose sarscov play eua guidance march launch ground important characterise vaccineinduced break cobas sarscov test run immune response majority current candidate widely available highvolume cobas vaccine aim induce antibody response system molecular test receive fda eua spike protein virus available country accept mark december announce partnership month later receive fda eua moderna inc use elecsys antisarscov highvolume elecsys antisarscov antibody antibody test modernas mrna vaccine test serology blood test specificity research trial facilitate quantitative great sensitivity day measurement sarscov antibodie help postpcr confirmation test help assess establish correlation vaccineinduce patient immune response virus protection level antireceptor bind launch viewic labop covid efficiency domain antibodie improvement laboratory september roche receive eua sarscov rapid antibody test launch fda cobas sarscov influenza test july intend qualitative detection igm use cobas systems test andor igg antibodie virus person intend simultaneous qualitative detection blood serum plasma blood mean differentiation sarscov influenza test determine influenza patient suspect havingdiagnostic roche total solution sarscov diagnosis develop record time include molecular immunodiagnostic solution clinical laboratory pointofcare settingsalong unparalleled rampup production capacity solution help well contain community spread virus provide quality highvolume testing help healthcare system respond effectively pandemic broad portfolio diagnostic solution develop launch respiratory viral infection available market accept mark urgent emergency care setting roche receive eua fda september cobas sarscov influenza test cobas liat system test provide result minute roche launch collaboration biosensor inc sarscov rapid antigen test market accept mark file eua fda quarter sarscov rapid antigen test use symptomatic people pointofcare setting test help healthcare professional identify sarscov infection people suspect carry virus result typically ready minute addition serve valuable initial screening test individual expose sarscovinfected patient highrisk environment december roche launch highvolume elecsys sarscov antigen test aid diagnosis sarscov infection test available country accept mark roche file fda eua perform healthcare professional test use swab sample patient sign symptom suggestive covid people know suspect exposure sarscov change standard care benefit patient apart sarscov test roche introduce important diagnostic advancement customer patient include broad test menu cobas system currently instrument place twice number project year instal indiagnostic roche advance accurate expansion help laboratory meet global need rapidly boost test testing laboratory covid help increase patient access solution drive future growth capability predict onset molecular business disease detect need cobas epsteinbarr virus ebv virus bkv test aim transplant patient run intervention individual cobas system grant breakthrough device designation bdd population level test fda approve ebv test august bkv test september fast reliable tool enable healthcare professional monitor treat patient risk common lifethreateningconsequence ebv bkv infection transplantation solid organ andor stem cell app algorithm image analysis algorithms launch september test qualitative help pathologist deliver rapid detection hiv hiv infections accurate test result oncology upath pdl cobas system receive fda approval algorithm nonsmall cell lung cancer worldwide hiv infection hiv hiv diagnosis upath dual ish algorithm infection largely limited people west herpositive breast cancer diagnosis africa hiv infection steadily increase europe immigration example cobas prime launch type virus route country accept mark transmission cause aid know fully automatic preanalytical specific strain help healthcare provider system prepare variety volume sample confidently treat patient effective lab receive molecular testing help therapy guide approach monitoring reduce manual work molecular labs clinical management september launch fdaapprove elecsys hiv duo fight covid roche immunoassay launch decision support solution navify remote monitor enable business school fda approve addition cintec restore operation consist mobile app plus cytology test cobas student employee web portal system september triage test organisation solution collect selfreporte base biomarker technology woman risk factor display recommendation base cervical cancer screening result positive official guideline facilitate decision highrisk type human papillomavirus hpv return work school advancement help drive lifesave revolution cervical cancer prevention treatment meeting need todayanticipate need tomorrow december launch cobas pikca covid demonstrate innovative mutation test country accept mark testing help spearhead innovative approach patient advance metastatic breast cancer patient care healthcare system management test detect mutation pikca advance accurate testing laboratory gene help clinician identify patient capability predict onset disease benefit targeted therapy support detect need intervention medical guideline individual population level drug development pandemic despite massive disruption global pandemic commitment develop new medicine remain unbroken thank range innovative approach phase iii empacta study meet primary development effort endpoint show patient covid effective improvement result associate pneumonia receive actemra new molecule move pivotal clinical roactemra plus standard care study compare approximately likely progress mechanical ventilation year year additionally death compare patient receive significant increase partner effort placebo plus standard care provide access latestage medicine statistical difference mortality patient time average recent receive actemraroactemra placebo year grant authorisation day study enrol patient population new medicine record underrepresented clinical study number new compound registrational disproportionately affect study file approval covid pandemic trial conduct brazil kenya mexico peru south africa search covid treatment early pandemic roche initiate remdacta global phase iii randomise double approach internal early research programme blind multicentre study initiate evaluate focus discovery medicine covid safety efficacy actemraroactemra test roche medicine approve plus antiviral remdesivir versus placebo plus disease large number potential remdesivir hospitalise patient severe collaboration covid pneumonia study conduct collaboration gilead sciences inc phase iii covacta study actemraroactemra enrolment begin june meet primary endpoint improve clinical status hospitalise adult patient august roche regeneron pharmaceuticals severe covidassociate pneumonia addition inc join force help address covid key secondary endpoint include pandemic develop manufacture distribute difference patient mortality week regeneron investigational antibody combination meet positive trend consist noncompete virusneutralise time hospital discharge patient treat antibodie casirivimab imdevimab november actemraroactemra fda grant emergency use authorizationpharmaceutical roche continue investment essential overcome devastating disease currently option patient approval grant medicine treat rare disease demonstrate important progress eua regeneron antibody combination inital medicine specifically test data phase portion ongoing study design treat condition today show reduction viral load decrease condition remain untreated medically attend visit nonhospitalise misdiagnose importance development patient covid additional datum well understand hypothetical example study expect early work think woman midthirtiesperhap health authority global health institution establish career start family concert collective response aim young child live life full achieve approval begin experience symptom nmosd prognosis grim overlay october roche atea pharmaceuticals inc statistic enter partnership develop manufacture people live condition distribute ateas investigational oral frequently misdiagnose multiple sclerosis directacting antiviral target covid people nmosd drive car people globe act block stop episode viral rna polymerase enzyme need viral onset stop work need replication currently study phase reduce work hour clinical trial hospitalise patient moderate patient require wheelchair covid phase iii clinical trial expect start functionally blind year quarter explore potential use patient outside hospital set enspryng design chugai member roche group build work conduct new medicine rare disease cns roche develop firstinclass treatment fda approval offer meaningful benefit neuroimmunological disease great example patient live rare disorder central commitment follow science order nervous system cns previously limited deliver groundbreake medicine treatment option enspryng satralizumabmwge complex difficulttotreat condition treatment rare disorder cns year dedicated effort collaboration neuromyelitis optica spectrum disorder nmosd fda approval enspryng exemplify patient evrysdi risdiplam people spinal industry academia work find muscular atrophy sma solution enspryng subcutaneous significant breakthrough patient treatment adult live nmosd evrysdi approve treatment spinal condition primarily damage optic nerve muscular atrophy sma adult child spinal cord cause blindness muscle weakness month age old life paralysis misdiagnose multiple people sma lose ability sclerosis recently people live nmosd perform critical physical movement sit upright loss function impact ability independently participate aspect daily life lifealtere treatment half baby type sma severe form die age clinical study evrysdi show clinically today people live meaningful improvement motor function people vary age differ level sma nmosd remain untreated severity include type infant achieve ability sit support misdiagnose second key motor milestone normallypharmaceutical roche achievable natural course disease evrysdi improve survival permanent ventilation age month compare natural history liquid medicine evrysdi administer daily home develop collaboration sma foundation ptc therapeutic evrysdi accomplishment achieve significant scientific breakthrough study placebocontrolle trial adult sma development medicine show interfere biology deep fundamental level target small molecule degree precision previously think possible expand portfolio cancer medicine gavreto pralsetinib receive fda approval treatment adult metastatic retaltered nonsmall cell lung cancer nsclc detect fdaapproved test oncedaily oral precision therapy design selectively target victoria school student child wheelchair ill ret alteration include fusion mutation live spinal muscular atrophy retactivate fusion mutation key disease driver cancer type include nsclc medullary thyroid cancer treatment option selectively target genetic alteration limit nsclc ret fusion represent approximately patient administer single injection administration gavreto perfect fit personalise approximately minute initial healthcare strategy excellent example loading dose approximately minute practice deliver target cancer medicine subsequent maintenance dose base genomic alteration success gavreto compare approximately minute demonstrate power understand sequential infusion loading dose perjeta person unique disease critical role herceptin standard intravenous nextgeneration sequence insight like formulation minute provide foundation medicine member subsequent maintenance infusion roche group play achieve well outcome medicine phesgo receive fda approval treatment european commission grant conditional early metastatic herpositive breast cancer marketing authorisation polivy polatuzumab fixeddose combination perjeta herceptin vedotin combination bendamustine hyaluronidase administer subcutaneous mabtherarituxan treatment people injection combination intravenous relapse refractory diffuse large bcell lymphoma chemotherapy candidate haematopoietic stem cell transplant polivy represent new offtheshelf phesgo medicine develop roche muchneede treatment option people combine monoclonal antibodie aggressive form lymphoma phcacross care continuum availability personalise care increase individual patient society benefit roche approach personalise healthcare organisation achieve well phc root combination advanced outcome patient society work diagnostic medicine datum analytic digital collective effort include patient technology goal serve provider payer policymaker regulator patient society large require holistic biopharma company technology company perspective entire healthcare system enable contribute unique perspective expertise experience roche instead view individual component confident combination deep patient care continuumprevention diagnosis scientific expertise holistic healthcare system treatment monitoringseparately roche approach close collaboration partner approach comprehensive system ecosystem personalised care integrate healthcare solution goal reality patient worldwide reduce complexity cost optimise patient societal outcome covid pandemic wakeup healthcare system expose systemic put patient centre care gap weakness time continuum establish high bar scientific demonstrate achieve research drive datum technology individual contributor join force drive datum insight system learn change innovation collaboratively outcome improve life benefit example roche partner local service provider canada italy spain establish use datum technology scientific mobile blood draw facility provide patient research rely trust patient safe timely comprehensive genomic commit transparency integrity profiling despite breakdown healthcare datum privacy practice work advance infrastructure inability local facility inclusive research globe ensure provide sufficient care scientific insight truly representative result new solution address need pandemic cause significant decrease broad diverse population furthermore number inperson doctor visit threaten roche invest new clinical trial design health patient manage disease generate insight real world type include neovascular agerelate macular insight improve patient outcome degeneration eye disease cause severe overall care experience vision loss help ensure patient manage thescience innovation roche sdgs material topic patient centricity efficiency personalise healthcare realworld data reparedness age society covid regular health check medical appointment followup treatment decline delay affect range disease area include cancer diabete disease central nervous system disease eye new technology help patient receive uninterrupted counselling safely reduce risk exposure physician staff especially pandemic digital pathology diabetes management example condition treat new technology disease continue care roche partner moorfields eye hospital united kingdom launch precommercial trial home vision monitor app patient access app smart device safety home test change vision function twice weekly care team remotely monitor patient disease progression detect need clinic visit roche found member insightthe health datum research hub eye health united kingdom aim build world large data resource ophthalmology datum combine advanced analytic result transform eye disease diagnose manage datum insight understand impact covid patient condition addition help ensure patient lifethreatene chronic disease receive uninterrupted care team roche data scientist epidemiologist create novel data analytic tool develop understand relationship mobility infection morbidity sarscov tool available local hospital test facility enable allocate resource effectively pandemic accelerate new era phc enable new avenue roche new paradigm practice today serve powerful catalyst accelerate use telemedicine digital tool allow patient care need minimise risk exposure reduce burden overload healthcare facility navify tumor boardscience innovation roche oncology partnership lie make phc reality global partnership groundwork personalise vision personalise healthcare measure success level improvement treatment healthcare option diverse access patient care experience include create adaptive learn ecosystem healthcare system worldwide achieve collaborative partnership base share vision purpose australia roche partner ministry health clinical network fight aggressive type cancer clinical trial specifically design specific form lung cancer increase patient access comprehensive genomic profiling cgp cancer applicable target therapy base test result trial potential improve patient prognosis serve blueprint make personalised healthcare clinical practice patient australia collaborate range partner healthcare sector contribute roche belgian society medical oncology unique expertise advancement patient bsmo join force transform cancer care care roche invest advance remote personalise diagnosis treatment monitoring tool need improve disease core programme study management timely care decision patient solid tumour receive cgp enable efficient use resource value cgp link therapy access use molecular tumour board goal research show nearly half chemotherapy sustainably deliver well outcome patient patient experience unplanne emergency establish new pathway funding department visit hospital inpatient stay innovative care cancer treatment event largely inadequately control symptom public private sector partner effect treatment include pain nausea roche denmark build secure virtual platform dehydration help address important encrypt anonymised data health issue roche collaborate fred hutchinson record oscar platform support fast institute cancer outcome research develop sustainable access personalise care digital remote monitoring system patient serve selfsustaine learn platform system potential greatly reduce healthcare system unplanne emergency visit inpatient stay enable early intervention improve similar effort canada hong kong south korea outpatient management singapore switzerland taiwan uae country demonstrate roche enter partnership harman effectiveness comprehensive interconnect international subsidiary samsung electronic solution include test clinical decision ltd create digital therapeutic platform support tool physician access right leverage virtual reality technology assist therapie innovative funding model individual autism spectrum disorder partnership combine technology device addition publicprivate cancercare experience deep knowledge neuroscience partnership globe roche effort develop innovative medicine hutchinson institute cancer outcome research hicor fred hutchinson cancer research center httpsnewsharmancomreleasesrelease new insight develop connect example flatiron health datum evaluate risk face herpositive breast cancer diverse realworld dataset patient take kadcyla specific pre exist heart problem analysis provide critical support research development insight suggest kadcyla worsen cardiac issue patient support optimise clinical decisionmake product label update european union inform prescriber patient important information year flatiron health foundation medicine partner ambitious project combine subset datum firstofitskind clinicogenomic database cgdb rapidly grow continuously update real accelerate research development world datum set serve key source datadriven datum medicine offer highquality longitudinal day data necessary optimal care clinical datum combine highquality genomic patient collect create large pool diagnostic data insight derive information know realworld datum database potential transform field datum reside individual patient new research regulatory patient record organise structure access application facilitate new care way allow healthcare provider option discern actionable insight improve care broadly patient turn cgdb action realworld data meaningful datum scale currently roche researcher leverage key generate new insight inform novel cgdb datum understand relationship transformative diagnostic therapeutic tumourgenomic feature clinical outcome tool support clinical decisionmake wide range tumour type clinical create healthcare ecosystem setting insight important continuously learn patient encounter consider target therapeutic development specific patient population selectively foundation medicine flatiron health member benefit therapy choice combination roche group forefront therapy approach additional development effort foundation medicine create opportunity give molecule genomic database flatiron health develop process curate harmonise clinical datum cgdb serve source external electronic health record virtual control arm tumouragnostic setting million patient result creation single drug treat cancer large representative deidentifie type genetic mutation biomarker clinical datum set innovative tool target drug certain situation insight derive scientist conduct randomise placebocontrolle trial engineer create currently include active experimental use cancer researcher worldwide traditional control arm difficult new type external control arm realworld data flatiron health utilise development cancer medicine rozlytrek evaluate benefitcost ratio treatment support regulatory approval japan perjeta firstline treatment setting datum help contextualise value perjeta future information new data type treatment earlystage breast cancer include image datum digital pathology andscience innovation roche foundationone test helped identify mutation cause patient bladder canceran aberration typical breast cancer patient treatment combination target therapy successful data wearable mobile phone app combine clinical clinicogenomic database yield insight help accelerate improve clinical trial programme delivery patient care furthermore type datum hold potential support access reimbursement decision patient benefit innovative treatment soon liquid biopsy advance personalise care august fda approve foundationone liquid cdx foundation medicine comprehensive pantumour liquid biopsy test patient solid tumour simple blood draw test identifie circulate tumour dna cancerrelate gene allow patient advanced cancer benefit comprehensive genomic profiling insight particularly tissue biopsy possible recommend insight help physician determine personalised treatment plan individual patient base specific mutation identify roche contribution advance personalise healthcare comprehensive system approach purposeful partnership patient worldwide receive well care combine advance diagnostic medicine datum digital technology roche continue serve connector catalyst seek purposeful partnership society establish integrate healthcare solution help global health system work well individual healthcare provider payer society large talk patient talk jennifer genomic profiling speak idea toolbox want use right treatment right time course treatment disease jeffrey rothenstein medical oncologist durham regional cancer centre oshawa canada read jennifers storyscience innovation roche pharmaceuticals clinical pipeline phase phase phase iii registration oncology inflammation immunology neuroscience infectious disease ophthalmology metabolic pipeline new molecular entity cover broad range disease highly innovative technology apply create produce active molecule accessfor everybodyworldwide pandemic prove important urgent work closely external partner improve access medicine crucial role play support active member industry stakeholder world access accelerate initiative focus face budget resource constraint noncommunicable disease ncd care need factor economic recovery low lowermiddleincome country lmic postcovid partner city cancer challenge make significant progress building capacity lifechange innovation medicine city level work city meaningful reach need population million world goal work partnership develop tailor people roche patient access solution create rapid broad support programme lmic sustainable access reason achieve increase population innovation reach need access cancer medicine herceptin portfolio consist primarily mabtherarituxan reach hospitaladministere treatment million require specialist skill infrastructure set goal increase patient access truly understand multidimensional nature breast cancer combination therapy herceptin access challenge translating plus perjeta emerge market grow global strategy country level sure patient understand key barrier global access program hiv testing patient benefit innovation see fourfold increase test run access strategy focus key pillar launch expand hiv include test mycobacterium affordability tuberculosis mtb hepatitis hbv capacity hcv human papillomavirus hpv lmic outcome certainty programme value significant priority roche measure work healthcare spectrumfrom impact join force boston government payer ngo multilateral university create roche monitoring insurance company specific evaluation framework framework provide example make significant progress consistent methodology evaluate social local international level patient impact access programme roche datum file httpswwwrochecommediareleasesmedcorbhtmaccess healthcare roche sdgs material topic ustainable healthcare system availability healthcare affordability healthcare working collaboration global partner healthcare spectrum enable increase access screen diagnosis treatment improve capacity local healthcare system nextgeneration medicine new diagnostic solution represent important option patient highlight need increase access therapy working boston universitys school public health give objective perspective assessment tool world quickly understand access initiative real impact ensure address right challenge understand need think differently support universal health coverage roche commit support universal health coverage uhc mean patient access essential quality health service face financial hardship recognise uhc important vehicle address inequality promote access quality medicine urgent need address huge inequity access healthcare worldparticularly lmic stand ready play advance uhc working partnership multiple stakeholder tailor solution create broad rapid access effort address health coverage inequality partner stakeholder supply chain different health service delivery point execute tailor solution focus key area support resilient healthcare systemswe actively support government effort build strong resilient healthcare system ensure access essential medicine diagnostic roche medicine essential medicine list roche provide test essential diagnostic list deliver tailor pricing solutionswe address affordability budget constraint different pricing model work insurer help introduce broad benefit package protect patient particularly affect ncds assist vulnerable group highincome countrieswe create programme patient support programme enhance accessaccess healthcare roche commit ensure responsible approach pricing commit ensure innovation reach innovation reach patient today patient today continue invest medical advance meet patient need tomorrow continue inv medical collaboration healthcare system partner use tailor pricing solution ensure advance meet patient need patient possible access innovation solution include tomorrow financebase agreement price volume cost sharing cap address concern affordability budget uncertainty performancebase agreement utilise realworld datum mitigate uncertainty benefit impact medicine payment accord level clinical health benefit achieve patientsupport programme design value patient limited option support patient manage outofpocket cost measurable launch new medicine international differential pricing idp rare disease cns approach recently update clear demonstration benefit approach provide framework align price public health system pay innovative medicine help cure stop innovative new medicine country slow disease progression improve quality life relative income take account countrys reduce medical complication avoid hospitalisation gdp public healthcare investment reduce need surgery prevent disability un human development index specific example include expect ensure broad fast access dramatic reduction aidsrelated death medicine country constrain hiv treatment economy enormous development cancer care enable cancer patient survive evolve pricing model meet need yearsan illness death focus develop new pricing model sentence innovative medicine increase model viral hepatitis case differ widely country country cure health system health system know concern improve alliance access covid therapy overall affordability medicine approach global pharmaceutical diagnostic company price fair responsible base issue joint statement collaboration key determinantsfirstly benefit medicine bill melinda gates foundation ensure bring patient family society secondly world population access covid local healthcare system reimbursement diagnostic future vaccine medicine regulatory context thirdly allow communiqu publish september continue sustainable longterm innovation total company include roche emphasise patient future commitment ensure poor country afford product need include innovation business model build allow donation distribution product cost continue risk need develop joint declaration life science company innovative medicine tackle sign respective ceo head complex disease area carry high risk pharmaceutical httpswwwwhointnewsitemwhorevealsleadingcausesofdeathanddisabilityworldwide httpswwwcancerresearchukorghealthprofessionalcancerstatisticssurvival httpswwwwhointnewsroomfactsheetsdetailhepatitisc partnership innovative fighting hivaid roche continue support hiv solution help break programme partnership global funder provide innovative laboratory barrier care improve patient solution work donor effective use resource order reach health outcome area patient place expand awareness roche partner nonprofit organisation great need red emphasise importance hiv diagnostic reach unaid goal aidsfree generation estimate year million hiv viralload test provide help patient monitor antiretroviral therapy eligible country addition laboratory professional africa receive training collaboration roche scientific campus johannesburg south africa roche develop solution specifically resource limited country include cobas plasma separation card easytouse sample collection portfolio cervical cancer solution automate testing device increase access remote area platform demonstrate commitment provide clinician mobile health application ithemba life laboratorie good tool possible protect women health deliver hiv test result education treatment appointment reminder directly phone india roche form privatepublic partnership focus building disease awareness improve testing quality maintain turnaround time programme work expert organisation clinton health access initiative chai metropolis partner national aids control programme share diagnostic expertise establish central lab build transport partnership increase capacity quality testing capability work eliminate hepatitis virus infection egypt high number hepatitis virus hcv infection world population infect early country launch massive effort eliminate disease nationwide screen treatment initiative roche work egypt government official healthcare agency provide robust dependable hcv diagnostic cervical canceraccess healthcare roche solution help manage achieve ambitious goal roche provide modern diagnostic system train healthcare worker ensure efficiency reliability screening programme target population million egypt screen million people million test positive hcv rna begin treatment eliminate cervical cancer cervical cancer remain lead cause death woman august world health organization launch global strategy accelerate effort eliminate cervical cancer public health problem strategy include target vaccinate woman hpv screen woman aged cervical cancer provide care woman diagnose cervical cancer new recommendation policy place roche begin work multiple ngo partner deliver reliable clinically validate hpv cancer screening tool sub saharan africa work closely ministry health kenya namibia nigeria south africa change guideline policy latin america local roche team develop comprehensive disease management solution support local cervical cancer programme example illustrate success effort chile woman screen cervical cancer result case going undetected woman develop advanced cancer roche partner ministry health stakeholder generate valuebase evidence use hpv screening centre hpv screening establish healthcare professional hcp educate primary care hcp chile woman screen brazil roche work university campinas indaiatuba municipality demonstrate value hpv screening form basis new hpv testing guideline roll hcp result city increase screen woman age month red division campaign global movement end extreme poverty preventable disease ministry health population egypt elzanaty associates egypt icf international egypt health issue survey cairo rockville ministry health population icf international wake screen treatment programme eliminate hepatitis egypt engl med mar support nurture diverse inclusive working environment address need diverse employee population inspire solidarity unlock potential people new way work diversity inclusion covid pandemic amplify agility roche tolerate journey change way work roche discrimination form embrace unique fast flexible bolder attribute people include age gender deepen connection purpose physical ability nationality sexual orientation special facet culture addressing culture life experience work thinking style multiple challenge result pandemic capability preference andor need require high personal engagement innovation cocreation proud contribution high level diversity refer mix achieve way deal wide range visible invisible difference unprecedented situation foster peopleand inclusion mean make acceleration transformation novel way mix work proactively sense successfully manage enormous task implement initiative create environment implement rapidly systematically people people feel strong sense belong constrained hierarchical boundary treat fairly respectfully equal empower idea practice access opportunity resource leverage vast breadth capability contribute fully organisation success critical result immediately evident transition work home wfh guide principle business day new collaboration tool human right ungps identify integral work roche pillar ethical humancentric business practice highly accurate sarscov test develop protect respect remedy roche fully manufacture launch amazingly short support implement ungps equally time frame effort identify possible committed support covid solution patient sustainable development goal sdgs global compact principle difficult time confirm belief universal declaration human right people great asset remain steadfast international labour organization declaration commitment ensure environment fundamental principle right work provide people nurture diverse global lgbti business standard roche inclusive group endorse standard httpswwwrochecomsustainabilityapproachhumanrightshtmour people roche sdgs material topic talent attraction retention organisational agility patient centricity roche commit ensure environment provide nurture diverse inclusive embrace people visible invisible difference support unfold capability work stay step withand ahead rapid massive transition work virtually ofcurrent standard right ensure protection employee thing prepare way business working site customer institute change trend indicate safety health protocol business interaction tertiary educate workforce woman offer roche elecsys people different ethnic background antisarscov antibody test roche millennial workforce employee world bringing change way work work hard pandemic home roche view engine innovation site significant impact people key success aim wellbee impact range feel reflect diverse workforce leadership isolation combat distraction come deepen global commitment lack control work environment strive achieve representation global society home roche global live activity employ people wide range background special focus give health wellbeing culture time covid additionally wide range employee assistance programme offer commitment great place globally include general tip wfh ergonomic work drive innovation roche dedicated mental health fitness mindfulnessresilience support work accordance nutrition social wellbee sdg achieve gender equality empower woman girl roche promote equal roche networked organisation opportunitie measure woman local regional expert empower reach leadership position key step find implement localise solution equality align local need situation constraint law regulation work global foster safe healthy workplace network able scale apply pandemic solution quickly covid alarm go benefit business continuity pandemicinfluenza significant adaptation way preparedness process initiate work enable make positive recent past prior planning enable difference patient thank measure manage protect business continuity site experience massive disruption production line ensure continuous development delivery medicine diagnostic solution patient tomorrow leadership commit carry positive element unprecedented experience ambition reflect global workforce demographic new normal ensure health safety senior leadership translate effort employee remain priority annual goal dynamically consider change strive maintain healthy workplace global workforce focus dimension employee encourage flexible work increase number woman key leadership position arrangement maximum extent possible increase number people key leadership local legislative environment position nationalitie underrepresented region continue learn well building network respective expert site empower expert active futureour people roche guide purpose local benchmark group order exchange information share learning significant adaptation way good practice company work make positive response covid pandemic conduct global employee opinion survey difference patient geo april goal pulse survey focus impact pandemic understand roche well support employee challenging time impressive result safety everyone responsibility rest eligible employee give feedback level management employee participant say feel support result establish practice reach roche come wellbee safety goal fiveyear period say feel proud work roche graph occupational health safety mindset continual improvement covid pandemic significantly build path success include set increase focus health safety series new fiveyear health safety goal unwavere ensure employeesand feasible ambitious complete work withare protect roche breakdown new goal visit view workplace website thirdparty manufacturer supplier clear category work task safe healthy order consistently fulfil commitment establish safe working practice proper procedure clear employee health safety direction employee fatal contractor accident happen roche basel clarify occupational accident feeling family victim prevention overexposure substance cornerstone protection health roche employee handle substance define necessary measure need know potencytoxicity substance level exposure cause operation year roche assess establish level acceptable exposure approximately substance apply systematically ensure goal exceed establish standard data place ensure protection losttime illness rate roche accident rate overexposure engineering control losttime accident rate number workrelate accident need new process design meet work day lose year accident threeyear average criterion exist one modify meet current standard containment httpswwwrochecomenvironmentourshegoalsandperformance extraordinary time people differencethose sure ill coronavirus disease continue receive care test medicine need story spotlight remarkable contribution outstanding employee rely strongertogether everyday herosour people roche everyday hero put patient flexcare transport enable covid pandemic detrimental effect patient doctor patient ability receive treatment multiple care start talk doctor effort undertake help ensure patient patient continue treatment interruption build idea alternative example represent wide site patient treat outside range effort hospital set lot understandable fear go hospital lara stallardtaylor roche australia important effort country high population people patient volunteer covid treatment centre immunocompromise go hospital receive colleague roche hungary train ocrevus treatment actually present high risk doctor volunteer hungary big covid infect sarscov result treatment centre inspire increase risk patient elect delay ocrevus treatment delay mean patient long control levente molnar roche hungary quickly clear alternative treatment doctor nurse grateful option need help patient kind help extremely safe ensure treatment interrupt stressful time provide regular quick quickly decide develop hometreatment feedback learn well programme bring ocrevus infusion directly day month pulmonology patient immediately core project group centre realise help formed significant network medical knowledge thing collaboration programme come learn agile transformation process quickly month typically require roche past year include visualise effort project begin summarise problem procedure month solution connect colleague diagnostic local doctor faith morilla edgar delasala roche philippine patient serve experience jano santha roche hungary sort disruption care take work hospital previously medical aback see number physician doctor different speciality altogether actually patient deteriorate arrive hospital week levente die period able able highlight area seek care huge action focus attention free time team immediately jump start specialist icu protect environment year society come expect corporation particularly area social responsibility transparency today stakeholder group expect corporation inspect facility environmental performance maximise environmental responsibility evaluate implementation policy entire supply chain roche compliance legal requirement corporate social responsibility ethical conduct internal standard team use result business respect human right evaluation stipulate future improvement commitment protect environment audit pharmaceutical diagnostic priority year facility regularly review present increase risk great frequency decade firmly believe environmental responsibility integral element standard entire supply chain good business behaviour mature environmental roche develop supplier code conduct management system ems ensures maintain hold supplier high standard high standard environmental responsibility responsible business ensure compliance internally supply chain inspector thirdparty auditor manage examine operation relevant internal operationsprevention key supplier necessary recommend company global production operation improvement roche expose risk possibly damage people good environment reputation alignment internal standard mature ems combine professional risk establish detailed performance expectation management minimise risk substantially thirdparty supplier individual roche local site business area serve line department act line control utilise control responsible implement audits assessment confirm contract standard set programme procedure manufacturer supplier service provider inspection selfassessment corrective meet expectation preventive action local safety security health environmental protection officer act internal process second line advisor roche business unit manager ensure control supplier sit group level meet local regulation adhere define control audit strategy corporate standard event noncompliance terminate contract refuse renew request second line control lie group level improvement actively assist audit team work specialist supplier implementingenvironment roche sdgs material topic energy efficiency longterm mindset roche aim maximise efficient energy usage cut energy consumption increase use sustainable energy source continue expand global business implement innovative technology continuously upgrade infrastructure improve energy efficiency expectation supplier clearly aim improve ecobalance communicate thoroughly enforce compare covid uncommon roche terminate collaboration pandemic improvement decrease partner operate responsible energy consumption air emission manner work minimise adverse reduce weight general chemical impact environment waste lead improvement approximately ecobalance continually minimise ecological footprint roche monitoring actively minimise fiveyear goal period conclude environmental impact year use end success reach concept ecobalance measure ecological environmental goal contribute significantly footprint result business activity decrease environmental footprint system allocate point ecologically relevant graph roche stakeholder parameter emission contamination resource clear company longterm future consumption waste etc provide commit uphold environmental global view impact earth responsibility support commitment ecosystem measure point total set new series fiveyear environmental size workforce able monitor goal ambitious feasible environmental impact level complete breakdown new goal small organisational unit visit website water consumption noise pollution energy consumption roche emission air emission water ecobalance landfille waste develop swiss federal office environment compliant late guideline httpswwwrochecomsustainabilityenvironmentourshegoalsandperformancehtmenvironment roche aim reduce emission responsible approach energy usage sustainability source emission roche commit sustainable energy future huge improvement area originate transformation recent year example increase share renewable energy aim maximise efficient use energy focus action energy usage cut energy consumption increase use sustainable energy source issue surround energy usage continue expand global business help reach goal set energysave action plan individual site plan include implementation innovative technology continuous upgrading infrastructure improve energy efficiency roche commitment sustainable energy extend individual customer work help increase energy efficiency aim reduce emission source design diagnostic instrument utilise reduce carbon footprint purchase energy little energy possible efficient equipment increase sustainable energy supply monitor employee convert roche supplier renewable travel need work process approach energy impact company set high expectation supplier energy reduce ghg emission approximately sustainability encourage conserve natural resource help convert improve water stewardship sustainable energy energy water major commodity pharmaceutical industry procurement organisation process world poor water quality result implement pilot project convert high purification cost increase risk supplier renewable energy share product contamination responsible user roche electricity rate obtain water roche uphold corporate sustainability corporate power purchase agreement offshore value contribute wellbee wind turbine energy ask supplier ecosystem community operate provide greenhouse gas protocol scope emission convert time roche operation remain renewable energy expose number associate risk factor allow roche measure exact carbon footprint roche site affect physical water reduction supply risk water stress drought regulatory risk impact business year aim reduce continuity scope greenhouse gas emission supply chain roche global procurement new environmental goal reduce set divisional goal increase number riskweighte water consumption employee green supplier year roche establish goal combat multitude water risk factor water stress track phase greenhouse gas progress goal roche develop energy roche come water risk metric account burn fossil fuel release carbon dioxide significant physical regulatory reputational greenhouse gas ghg atmosphere risk factor promote responsible waste management commitment product stewardship demonstrate concern waste generate patient customer product actively support responsible management waste product end life diagnostic division assemble team provide guidance relate operational waste generate production site liquid waste consumable package result operation diagnostic instrument team look good way decommission instrument end life example recent guidance decommissioning include detailed information component require special handling safety environmental standpoint template contract instrument recycling vendor ensure roche requirement apply uniformly worldwide process evaluate recycling vendor ensure capable responsibly manage recovery recycling disposal process deliver innovative test responsibility pharmaceutical division genentech stakeholder minimise impact diagnostic manage product takeback council ptc product safety security health environment partnership diagnostic division entire product life cycle diabetes care business ptc cover takeback programme unused medicine medical sharps lancet needle disease management regulatory compliance ptc establish criterion help product team understand key element good well good takeback programme guide deliver high level patient support product promote safe disposal sharps diabete care participate financially support collaborative effort pharmaceutical medical device manufacturer nonprofit actively support responsible organisation collaboration result significant improvement accessibility management product end quality information proper disposal patient caregiver change behaviour life responsible disposal sharpsenvironment roche evergreener roche environmental goal like industry past roche come close success area clear affiliate company landfill dispose sign roche take environmental responsibility chemical solid waste roche seriously founder set course advocate incineration hazardous waste greener future keep momentum suitable alternative today roche affiliate goingwith proactive mindset roche globe direct refrain greener performance early send organic chemical waste potentially clear demonstration commitment success harmful substance landfill reduce energy action aim reduce environmental consumption scope approximately impact minimum commit operating employee drive decrease energy budget nature leave consumption parallel decrease use stable living environment future fossil fuel emission consequently generation help journey success decrease approximately employee roche site worldwide develop roadmap period strategy clear sustainable energy future clear business order continually set monitor challenge realistic reduce energy intensity energy usage environmental goal monitor new employee substitute remain environmental goal carefully energy energy generate sustainable source strategy electrical power consume roche come sustainable source take approach roche position ahead climate change scenario publish intergovernmental panel climate change look forward roche longterm goal reduce greenhouse gas ghg emission own control source generation purchase energy zero ghg emission roche originate transformation use energy roche founder set low ghg emission roche opt energy efficient technology example headquarters course greener future switzerland integrate thermal network new building use reject evergreener waste heat fiveyear goal share sustainable energy landfilling organic chemical ton greenhouse gas emission tcoeq scope employee halogenate hydrocarbon roche legacy site ton fey lom yep ion general waste kgemployee water consumption memployee goal ffe fossil fuel equivalent weight water stress change relate energy consumption terajoule total scope scope energy scope scope consumption gjemployee datum collect group gigajouleenvironment roche coequivalent emission tonne scope fuel combustion halogenate hydrocarbon scope scope business flight scope direct emission generate facility scope indirect emission purchase energy scope indirect emission include scope value chain marketbase datum halogenate hydrocarbon tonne inventory consume release global inventory include chugai genentech ventana emission air tonne voc particulate nitrogen oxides sulphur dioxide volatile organic compound water usage discharge water withdraw million water consume million organic matter discharge waterway treatment heavy metal discharge waterway treatment landfille incinerate waste tonne general waste generate chemical waste generate contaminate soil construction waste contaminate soil remove reduce remediation activity kesslergrube germany support community pandemic roche philanthropy help community live workand beyondface covid crisis roche long history philanthropic result people screen engagement clear strategy focus virus addition phelophepa healthcare remain strongly commit staff run mental health workshop help partner community serve community cope mental stress fear philanthropic pillar humanitarian aid anxiety stem pandemic environment education art emergency appeal continue fulfil commitment accord united nations high commissioner support change focus related covid refugee unhcr kenya host fifth increase support area high number refugee africa refugee large impact year extraordinary population half million people condition greatly increase importance refugee live dadaab kakuma community support respond global camp locate isolated part appeal support new humanitarian project country insufficient national health system capacity covid arrive prevention region concern safety individual roche main external sponsor south increase considerably africa phelophepa healthcare train year proud continue support unhcr issue global emergency appeal programme serve important element fund protect refugee roche respond south africa response covid crisis donation go refugee camp train operate partnership urban area host refugee south african ministry health transnet fund provide range muchneede countrys main freight logistic company material include soap sanitiser ppe medical supply portion donation addition annual sponsorship roche go improve water sanitation hygiene donation friend phelophepa facility train rapid response team raise employee foundation provide personal protective awareness hand hygiene set equipment ppe sanitise equipment isolation centre train healthcare worker safe possible donate mask hygiene campaign roche respond emergency appeal material staff use community small nongovernmental organisation outreach effort ngo make significantcommunity roche sdgs material topic longterm mindset availability healthcare prior pandemic primary service offer phelophepa healthcare train optical dental wellness psychology service halt order focus stop spread virus underserve rural area phelophepa healthcare train react employee foundation begin new project ngo child dream support quality education cambodia despite pandemic roche employee find creative safe way annual tradition fundraise youth educationthe children walkgoe impact example foundation esther fayulu request funding kimbondo large orphanage democratic republic congo support helped provide disinfection premise purchase distribution mask hygiene equipment food infant child month digital hardship relief student young people study develop country poor internet bandwidth limit access computer online learning challenge roche help meet need hundred student world emerge market scholarship programme education partner fundacin educacin support university student colombia salvador guatemala peru organisation take challenge digital relief fund design build technical infrastructure digitise education programme roche contribute fund lend laptop prepay mobile card ensure student access online course addition support hardship relief fund support student struggle cover basic need difficult time provide hardship relief partner include maharishi institute provide holistic university education student johannesburg south africa kiran children village support high education student poor family india roger federer foundation provide child attend early childhood development programme malawi food information covid preventioncommunity roche remain strongly committed walk like year roche employee partner community globe come participate global fundraising event roche pandemicsupporting wide range children walk event support roche employee action charity trust react response plan local children charity project gather restriction employee site country find creative waysrange virtual auction walk placeto continue join force raise money charity react partner continue support children project crisis employee foundation begin new partnership child dream support child youth cambodia laos myanmar thailand fiveyear commitment helping improve access education cambodia provide quality school building benefit student computer lab facility student scholarship marginalise highschool disaster help community student child dream build new school classroom complete new rebuild computer lab facility student provide scholarship commitment society roche philanthropy support community rebuild effort begin support new project significant disaster example day fund jakartabase ngo reduce stunting child indonesia design follow explosion lebanon august reduce stunt build contribute broad spectrum relief effort evidence good way sustainably tackle country confirm safety employee problem ensure immediate assistance need contribute number emergency response secondment digital rebuilding initiative donate rocephin roche antibiotic global philanthropic secondment programme hospital healthcare centre experience shortage allow share company employee replace damage diagnostic laboratory equipment expertise ngo helping improve support international committee red cross global health education community donation emergency medical supply donation world education partnership rebuild severely impact healthcare institution swissbase ngo promote knowledge exchange provide support local ngo cancer fund company europe universities africa begin offer virtual career starter january australia face unprecedented programme arrange roche unrelenting bushfire roche donation employeesfrom global insight digital australian red cross disaster relief recovery fund engagement people culture nigeria helped provide people living evacuation ghanato coach recent graduate centre food water basic necessities namibia university science technology university namibia meet high standard business ethic provide meaningful benefit society uphold high standard ethic integrity sustainability roche convince integrity foster culture integrity remain basis sustainable update coc incorporate topic successful business today employee emerge interest roche stakeholder investor customer stakeholder view topic include digitalisation personalise topic ethic integrity sustainability healthcare information governance realworld increasingly vital employee datum human right roche responsibility behave integrity act conduct activity design inform accordance share company value educate foster spirit key message go far comply law include coc month focus regulation make positive impact specific compliance topic discrimination society business endeavour harassment datum privacy conflict interest activity provide information effort include strengthen stakeholder topic variety tool include quiz understand ofand trust inour business infographic animation order increase respect remain independent political acceptance empower people affiliation spend chf million foster inclusive approach activity switzerland include payment industry material cocreate affiliate association chamber commerce function reflect diversity inclusion financial assistance trade union donation organisation way able devise political party cantonal federal level activity tailor address local need donation political party low addition increase awareness understand doubledigit thousand range swiss franc compliant business behaviour employee account approximately encouraged speak potential total contribution donation violation coc encounter share concern multiple line launch update roche group manager compliance officer code conduct coc clearly define roche group speakup line expectation business behaviour provide box detail practical guidance clear example coc serve business card specifie adapt policy meet change need commitment make valuable significant covid pandemic sustainable impact society receive increase number request deliverbusiness ethic roche sdgs material topic human right ethic transparency patient centricity availability healthcare compliance roche convince integrity remain basis sustainable successful business include safeguard highquality supply require supplier service provider protect support human right jointly enhance sustainable value require business partner distributor supplier service provider meet integrity standard enter business relationship perform riskbase diligence potential partner supplier successfully complete diligence process commit roche principle ethic sustainability define supplier code conduct scoc conduct onsite audits ensure highrisk supplier adhere scoc pay particularly close attention industry know employ vulnerable population highvolume supplier supplier highrisk location roche update scoc ensure alignment coc context great emphasis sustainability expect supplier help foster social environmental economic development contribute sustainability community operate illuminate example sustainability effort local level find medical waste recycling shanghai china china world second large medical roche big workforce locate san francisco device market improper medical waste basel management cause environmental pollution roche collaboration thirdparty company develop implement innovative process safe disposal diagnostic instrument sustainable medical waste treatment process medicine diagnostic free charge adopt competitor donate personal protective equipment food successful collaboration roche set essential item believe find medical device industry benchmark sustainable sustainable solution good serve patient medical instrument disposal work alongside healthcare stakeholder example successful local effort come light current global crisis add information technology large specific guidance covidrelate request company outsource job farflung part principle order address urgent world roche big workforce question issue unprecedented locate san francisco basel time want ensure help timely create share service centre roche manner maintain compliance place like kuala lumpur budapest guidance helps understand activitiesand san jose centre run internal roche particular related fair distribution employee small key partnership structure allocation productsare allow put well position protect human right infringe regulation action subject time develop talent locally local law internal policy countriesbusiness ethic roche supplier commit manage risk opportunity expressly commit sustainability principle order guide principle business human right enforce commitment affiliate work supplier worldwide roche proud pharmaceutical supply chain initiative psci group pharmaceutical healthcare company commit improve social health safety environmental outcome community time record deficiency management supplier locate framework system finding relate emergency exit psci roche driving force lack fire drill conduct development industrywide process well identify prevent violation human example illustrate partner right environmental standard supplier supplier help increase human right standard expect supplier comply quality trucker force perform standard strict principle ethic job unsafe condition employer work condition environmental protection obey labour law perform ssav health safety require deal trucking company major logistic risk appropriately ensure supplier able interview employee business continuity subsupplier management present result positive human right supplier risk embed supplier violation find base successful pilot life cycle tailor risk management approach plan perform audits truck driver supplier type risk present audit finding support petition mean certain highrisk supplier assess different company government frequently country build safe rest stop trucker regard supplier service provider partner traditional audit concept ensure standard uphold conduct supplier sustainability assurance visit ssavs goal create mutual trust add value goal stand contrast conventional audits regard monitor mission roche work supplier compliance bring compliance standard attempt bring supplier compliance supplier remain employee roche group speakup unable meet roche minimum requirement line operate external provider available reconsider engagement supplier language countrie chief compliance officer include termination business receive report allege violation code relationship conduct business ethic incident reporting system unfounded found conduct ssavs safety investigation result employment contract security health environment audits agreement business partner terminate worldwide main finding relate excessive ground unethical behaviour overtime andor inadequate compensation overtime ineffective maintenance employeessenisub ecnamrofrepbusiness performance roche group sale increase constant exchange rate cer decline swiss franc result continue appreciation swiss franc currenciessale chf million roche group roche pharmaceutical roche diagnostic puorg ehcor sdg material topic longterm mindsetbusiness performance roche group sale rise chf medicine regular visit health practice chf billion core operating profit increase hospital need infusion chf reflect underlying business people continue avoid visit doctor performance core eps grow chf partly compensate additional sale ahead sale appreciation swiss franc actemraroactemra treatment currencie significant patient severe covidassociate adverse net impact result express pneumonia swiss franc compare constant exchange rate diagnostic division report strong sale ifrs net income increase chf growth chf billion growth increase mainly low goodwill primarily worldleading portfolio new writeoff compare previous year covid test molecular diagnostic main growth contributor drive molecular sale pharmaceutical division decrease covid test chf billion mainly strong expect biosimilar competition sale diagnostic sarscov develop covid pandemic new medicine launch year emergency testing clearly exceed continue strong growth covidrelated decline routine diagnostic chf billion generate sale sale additional product launch fourth chf billion contribute quarter spike antibody test division total sale covid vaccine trial underline roche speed innovation power sale new medicine grow strongly impact competition biosimilar outlook establish medicine herceptin avastin despite continue strong impact biosimilar mabtherarituxan significant estimate sale expect grow low midsingle combine chf billion sale reduction digit range constant exchange rate core europe japan earning share target grow broadly line sale constant exchange rate covid pandemic overall negative roche expect increase dividend swiss impact division sale especially franc growth rate report constant exchange rate cer average topselling product portfolio chf million scitsongaid cobas immunodiagnostic cobas virology ventana advance stain cobas blood screen accuchek diabete carebusiness performance roche apart sarscov test roche growth report emea north america latin america japan introduce important sale decrease asiapacific drive china decrease routine test diagnostic advancement follow severe covid pandemic restriction customer patient addition broad new covid testing portfolio roche introduce important diagnostic advancement customer patient include cobas prime fully test product sarscov rapid automatic preanalytical system prepare antigen test north america decline variety volume sample lab receive offset roche custombiotech business molecular testing nextgeneration product solution diagnostic biotech upath image analysis algorithm rapid manufacturer accurate test result oncology digital pathology automate analysis scan generate sale molecular diagnostic increase tissue sample strong sale growth drive segment virology predominantly sarscov roche market first include cobas highthroughput pcr test launch march epsteinbarr virus ebv virus bkv test lightmix system pathogen detection panel approve fda midyear pointofcare molecular diagnostic test previously receive breakthrough device status fast reliable tool perform diabete care sale decrease patient highthroughput cobas system switch continuous glucose monitoring system enable healthcare professional monitor treat covid pandemic negative impact patient risk common lifethreatening decrease reflect mainly emea consequence ebv bkv infection region demand digital diabetes management transplantation solid organ andor stem cell solution rochediabete care platform mysugr accuchek sugarview continue strong centralise point care solution sale decline immunodiagnostic business tissue diagnostic sale increase strongly impact decline routine growth advance stain instrument sale testing worldwide particularly china recovery manufacturing delay prior year covid pandemic emea decline increase sale companion diagnostic routine testing compensate partially offset low testing volume sale growth pointofcare covid covid pandemicslacituecamrahp incremental sale chf million tecentriq oncology hemlibra haemophilia ocrevus neuroscience actemraroactemra immunology perjeta oncology kadcyla immunology alecensa oncology gazyvagazyvaro oncologybusiness performance roche despite massive disruption united states sale decrease result increase competition biosimilar global pandemic commitment mabtherarituxan herceptin avastin combine partially offset sale develop new medicine remain ocrevus hemlibra tecentriq actemra roactemra ocrevus sale drive new unbroken return patient demand partly dampen covid effect tecentriq sale increase mainly growth new indication certain form lung breast liver cancer europe sale grow new product sale compensate biosimilar competition herceptin mabtherarituxan avastin combine impact perjeta approve chf billion covid pandemic tecentriq sale continue herpositive breast cancer increase grow strongly follow successful launch patient demand medicine drive hemlibra ocrevus show strong uptake international region mainly china early breast cancer metastatic breast cancer japan sale decrease result setting considerable competition biosimilar government price cut decline partially tecentriq approve chf billion compensate recently launch product cancer immunotherapy type include tecentriq hemlibra perjeta sale cancer combination certain grow launch additional indication type lung bladder breast liver cancer early breast cancer strong sale growth report region notably high sale drive international region sale growth new indication extensivestage small cell lung drive china russia china cancer pdlpositive triplenegative breast cancer see strong uptake perjeta alecensa unresectable metastatic hepatocellular partially offset impact national carcinoma reimbursement drug list update covid hemlibra approve chf billion ocrevus approve chf billion haemophilia factor viii relapse primary progressive form inhibitor prophylactic treatment multiple sclerosis short hour infusion administer subcutaneously weekly strong demand treatment indication week week sale continue covid pandemic continue strong uptake especially certain negative impact growth europe despite covid restriction drive new return patient impact potential new patientsetaroproc ecnanrevogcorporate governance roche corporate governance report set structure process rule roche take basis wellfunctione corporate governance material topic compliance principle business activity focus sustainable particular applicable law swiss stock value creation innovation management exchange swiss exchange directive culture conform recognise standard swiss code good practice corporate good corporate governance policy governance promulgate swiss business transparent communication embody roches federation economiesuisse company internal corporate governance principle build governance framework particularly article basis successful implementation roche incorporation bylaw embody commitment serve stakeholder principle need ensure company business manage supervise manner strong board director represent consistent good corporate governance interest shareholder include necessary check balance stakeholder highly skilled manager act integrity extremely important print annual report contain select link roche website httpswwwrochecom eleventh time roche rank reader provide snapshot sustainable company pharmaceutical company report date index dow jones sustainability indices direct source consult djsi recognition base indepth time uptodate information corporate analysis economic social environmental governance roche annual report performance djsi serve benchmark cover single financial year end december investor integrate sustainability consideration website contain information portfolio sustainability core permanent nature late roche news business practice award reflect company article incorporation bylaw commitment run business way curricula vitae current status ethical responsible create longterm value end term report date stakeholder december year year member board director corporate governance report set corporate executive committee publish structure process rule roche website take basis wellfunctione corporate governance roche complie detail refer follow relevant corporate governance requirement report httpswwwrochecomaboutgovernancehtmcorporate governance roche annual general meeting annual general meeting board director board director board committees board committee chairmansnomination committee remuneration committee audit committee corporate governance sustainability committee corporate executive committee corporate executive committee ceo ceo ceo chief financial chief people roche group pharmaceutical diagnostic information officer officer enlarge corporate executive enlarge corporate executive committee committee gre pre partnering communication general counsel board director federal council declaration andreas oeri prof sir john bell retire extraordinary situation base article longstanding member board director epidemics act september jrg duschmal new representative pursuant ordinance measure combat shareholder group pool voting right coronavirus covid ordinance amendment patrick frost elect additional march annual general new member board director term meeting agm roche holding ltd hold year march physical participation shareholder shareholder request addition agm elect christoph franz exercise right independent proxy andr hoffmann prof richard lifton testaris bernard poussot member remuneration committee agm roche holding ltd march shareholder reelect christoph franz organising meeting immediately follow chairman board director agm board director determine structure composition remain furthermore agm reelect andr hoffmann committee show julie brown paul bulcke prof hans clever anita board director corporate hauser prof richard lifton bernard poussot executive committee severin schwan claudia suessmuth dyckerhoff member board director roche honorary chairman fritz gerber term year provide article die age year incorporation decade shape roche board director board director board committees board committee chairmansnomination committee remuneration committee audit committee corporate governance sustainability committeecorporate governance roche development lead global healthcare lifton bernard poussot reelection company exceptionally successful dual role member remuneration committee group ceo chairman agm board director board director nominate testaris march forthcoming agm election independent proxy agm board director nominate chairman period conclusion remain member board director ordinary agm shareholder reelection board director nominate christoph franz andr hoffmann prof richard composition year birth elect board director christoph franz chairman andr hoffmann representative vicechairman shareholder group pool voting right jrg duschmal representative shareholder group pool voting right julie brown paul bulcke prof hans clevers patrick frost anita hauser prof richard lifton bernard poussot severin schwan claudia suessmuth dyckerhoff secretary annette luther april board directors curricula vitae cvs member board director current member httpswwwrochecomaboutgovernanceboardofdirectorshtm bformer member year httpswwwrochecomaboutgovernanceecbodformerhtm information cvs report date december year year httpswwwrochecomaboutgovernancearchivformercvshtm corporate governance sustainability committee audit committee remuneration committee chairmansnomination committee nonexecutive director executive director independent member board directors committee chairperson corporate executive committee gottlieb keller general counsel member effective august aviv regev corporate executive committee secretary chair faculty core institute member board director retire year member executive leadership team roche end march broad institute mit harvard professor biology mit investigator board director appoint claudia howard hughes medical institute join genentech bckstiegel head legal new head gre report member diagnostic division position general enlarge corporate executive committee counsel april report severin schwan member enlarge corporate executive committee severin schwan information member corporate executive committee enlarge corporate parallel annette luther general executive committee list manager roche diagnostic international ltd board director rotkreuz switzerland secretary corporate executive committee board director report christoph franz effective july michael varney head genentech research early development gre member enlarge corporate executive committee retire company year corporate executive committee corporate executive committee ceo ceo ceo chief financial chief people roche group pharmaceutical diagnostic information officer officer enlarge corporate executive enlarge corporate executive committee committee gre pre partnering communication general counselcorporate governance roche composition year birth position corporate executive committee severin schwan ceo roche group bill anderson ceo roche pharmaceutical thomas schinecker ceo roche diagnostic alan hippe chief financial information officer cristina wilbur chief people officer enlarge corporate aviv regev head genentech research executive committee early development gre william pao head roche pharma research early development pre james sabry global head pharma partner barbara schdler head group communications claudia bckstiegel general counsel secretary corporate perolof attinger executive committee statutory auditor kpmg klynveld peat marwick goerdeler reporting year roche holding ltd kpmg auditor charge ohn morris ian starkey mark baillache business year chief compliance officer pascale schmidt curricula vitae cvs member corporate executive committee enlarge corporate executive committee current member httpswwwrochecomaboutgovernanceexecutivecommitteehtm bformer member year httpswwwrochecomaboutgovernanceecbodformerhtm information cvs report date december year year httpswwwrochecomaboutgovernancearchivformercvshtm group structure shareholder roche operate business organise shareholder relate party page division pharmaceutical diagnostic note financial statement pharmaceutical division comprise roche holding ltd significant shareholder business segment roche pharmaceutical addition significant shareholder chugai genentech publish relevant webpage link segment integrate roche disclosure office exchange regulation pharmaceutical diagnostic division consist follow business area centralise andr hoffmann vicechairman board point care solution molecular diagnostic director chairman remuneration committee tissue diagnostic diabete care board corporate governance sustainability committee member board business activity carry group chairmansnomination committee jrg subsidiary associate company detail duschmal member board director information roche holding ltd significant board audit committee serve respective subsidiary associate company include capacity board committee company list information domicile share representative shareholder group capital equity interest list finance pool voting right receive remuneration report note roche group consolidated set forth remuneration report financial statement list subsidiary finance report note roche associate group consolidated financial statement relate party relationship exist major shareholder list finance report shareholder pool voting right note roche group consolidate financial statement equity attributable roche crossshareholding roche pharmaceutical incl genentech pharmaceutical chugai centralised point care solution molecular diagnostic diagnostic tissue diagnostic diabetes care composition exchange regulation httpswwwseragcomenresourcesnotificationsmarketparticipantssignificantshareholdershtmlcorporate governance roche duschmal hoffmann jrg duschmal member audit committee andr hoffmann chairman corporate governance sustainability committee remuneration committee capital structure information roche capital structure addition nonvoting equity security provide finance report note nes issue bearer form financial statement roche holding ltd form share capital confer vote additional detail contain right ne confer right article incorporation roche holding ltd share participate available earning liquidation proceed follow repayment movement recognise amount share capital roche ne right pertain financial year detailed finance thereto include provision protect report note financial statement roche interest ne holder describe hold ltd article incorporation roche holding ltd company share capital information debt instrument chf divide fully issue outstanding bond provide pay bearer share nominal value chf finance report note roche group restriction exercise consolidated financial statement debt voting right share deposit share vote restriction information employee stock option provide finance report note roche authorise conditional capital group consolidate financial statement equity httpswwwrochecomaboutgovernancearticleofincorporationhtm compensation plan include detailed note roche group consolidated financial information stocksettle stock appreciation statement equity compensation plan right ssar plan restrict stock unit option issue connection debt rsus plan performance share plan psp instrument roche connect roche option plan option award employee roche issue option apart employee debt instrument issue stock option describe finance report effect roche share capital board director corporate executive committee information member board exception severin schwan director member corporate member board director executive committee list page office end member member board director age limit roche corporate executive committee restriction term office serve executive capacity group subsidiary financial year precede curricula vitae cvs current current reporting period member year lack exist business connection body information include information group subsidiary independent roches board year election additional director independence definition base position membership activity available definition swiss code good practice continuously update internet corporate governance economiesuisse addition status cvs body complement specific precede criterion relevant reporting date december httpswwwrochecomaboutgovernance year separately available boardofdirectorshtm rule pursuant article para point vegv principle governance principle number permit activity board delegation competence reservation power director corporate executive committee management group company member outline article executive body company include economic incorporation roche holding ltd environmental social topic principle internal organisation annual general meeting elect board director division authority member board director chairman responsibility board management board director member remit board committees remuneration committee annual basis information control mechanism available election nominee vote board dealing corporate management separately article incorporation govern bylaw roche holding ltd minute annual general meeting roche holding ltd hold board director roche holding ltd march organise ensure group conduct httpswwwrochecomaboutgovernanceboardofdirectorshtm httpswwwrochecomaboutgovernanceexecutivecommitteehtm httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecomaboutgovernanceannualgeneralmeetingshtm httpswwwrochecomaboutgovernancearticleofincorporationhtmcorporate governance roche board director board director board committees board committee chairmansnomination committee remuneration committee audit committee corporate governance sustainability committee corporate executive committee corporate executive committee ceo ceo ceo chief financial chief people roche group pharmaceutical diagnostic information officer officer business responsibly focus report operate financial risk risk longterm value creation end roche management system board delegate certain responsibility roche group establish risk committee composition management process cover entire company chairperson december describe system place identify manage committee authority type risk potentially affect business responsibility define detail include economic environmental social bylaw board director impact risk opportunity stakeholder input committee chair independent board director high governance director body involve roche risk management policy set approach accompany accord bylaw board director responsibilitie pharmaceutical board meeting convene diagnostic division global function conduct chairman present request formal risk assessment process member roche board meet year year develop risk plan assess chairman performance meeting material risk monitor deviation attend chairman chair review regular performance dialogue vicechairman consolidated group risk report include target risk profile discuss corporate management information system mis executive committee approve board director regularly inform group business plan material risk important issue sale performance etc review board yearly basis board access electronic information effectiveness risk management process platform provide timely information monitor group risk advisory team board director board committee overall process regularly review system control set forth external auditor finding present audit committee board board director establish system detail risk management include risk control continuously monitor factor risk management policy audit committee corporate governance risk management website financial sustainability committee board risk management specifically describe director consist follow element finance report httpswwwrochecomaboutgovernancecommitteeshtm httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecomsustainabilityapproachriskmanagementhtm additional information provide finance report note roche group consolidate financial statement risk management system internal control financial reporting director report person agenda finance report item concern situation warrant internal audit member enlarge corporate executive group audit report general counsel committee invite attend board direct access give regular briefing committee invite chairman board audit committee corporate corporate executive committee member deliver governance sustainability committee report committee meeting elect ongoing activity audit report chief commission independent expert report audit risk advisory executive attend audit service consultant committee partly corporate governance sustainability committee meeting year blackout period impose external auditor group audit independent member board director appraisal function evaluate review senior employee prohibit trading group activitie service board company stock follow blackout period director management annual audit effect plan yearly define focus area market december february access thirdparty management validate april april senior management approve audit june july committee roche group commit october october maintain high standard internal control blackout period change chairman worldwide operation management board director circumstance warrant responsible assess business risk aspect operation implement board director meet meeting effective efficient process control generally hour length include whilst ensure compliance internal fullday meeting covid pandemic external rule regulation board director hold additional conduct operational audits group audit extraordinary meeting include determine management response risk abovementione figure plan day visit surround business process system major subsidiary board director evaluate appropriateness completeness cancel efficiency process control action plan implement necessary change board committee meet follow enhancement develop chairmansnomination committee meeting businessauditee track completion approx hour statutory auditor remuneration committee meeting approx chief compliance officer compliance officer hour subsidiary audit committee meeting approx hour safety health environmental protection department corporate governance sustainability corporate sustainability committee committee meeting approx hour science ethic advisory group seag issue relate genetic engineering board director regularly conduct assessment selfassessmentassessment member corporate executive committee party electronical survey personal invite attend meeting board interview performance httpswwwrochecomsustainabilityenvironmenthtm httpswwwrochecomsustainabilityhtm httpswwwrochecomresearchanddevelopmentwhowearehowweworkethicsinrdethicalconflictshtm remuneration committee member recuse deliberation decision matter affect interest figure indicate actual length meeting include director extensive premeete preparation postmeete followup activitiescorporate governance roche member corporate executive committee maximum ordinary notice period month changeofcontrol clause employment contract management contract fall scope subsection annex directive information relate corporate governance andr hoffmann chairman corporate governance sustainability committee attendance board board committee meeting corporate governance chairman nomination remuneration audit sustainability board committee committee committee committee number meeting franz hoffmann brown bulcke clevers duschmal member board march frost member board march hauser lifton poussot schwan suessmuth dyckerhoff bell retire march oeri retire march member committee member march member march remuneration shareholding loan detail remuneration shareholding rules aol loan content method determine content board cec compensation shareholding programme rule principle basic principle element compensation applicable performance shareholding programme serve related pay member board director corporate rule principle executive committee description allocation equity security authority procedure determine convertible right option set forth separate remuneration report additional page finance report payment member note roche group consolidated executive committee financial statement equity attributable roche appoint vote shareholder relate party page pay annual general list note financial meeting shareholder statement roche holding ltd board rule loan credit facility executive shareholding postemployment benefit rule vote pay follow rule remuneration shareholding agm loan board director board corporate executive committee cec set forth article incorporation aoi httpswwwrochecomaboutgovernancearticleofincorporationhtmcorporate governance roche participatory right shareholder participatory right shareholder define article incorporation roche article incorporation roche shareholder represent share nominal share issue bearer restriction value chf million request admission annual general meeting placement item agenda annual exception share deposit general meeting later specify period date meeting day date meeting admittance card issue shareholder provide article rule issue instruction incorporation shareholder elect independent proxy rule electronic represent party annual general participation annual general meeting meeting lay correspond invitation annual general meeting regulate article incorporation contain restriction article incorporation exercise voting right quorum requirement stipulate conformity swiss code obligation change control defensive measure article incorporation contain provision nonvoting equity security terminate mandatory bid rule swiss law apply event acquisition vest period restriction preexist award changeofcontrol clause remove option exercise component remuneration base roche immediately httpswwwrochecomaboutgovernancearticleofincorporationhtm relationship statutory auditor annual general meeting roche holding ltd service agree audit committee march shareholder vote potential nonaudit service engagement appoint kpmg kpmg statutory auditor review policy authority proceed give base exist legal requirement swiss code obligation article auditor direct access audit concern maximum term office seven committee chair head group year auditor charge mark baillache audit discuss relevant issue auditorincharge business year information long auditor report statutory auditor auditorincharge serve consolidated financial statement capacity provide statutory financial statement find page auditor participate audit committee meeting respectively finance report prepare write oral report result audits audit committee oversee kpmg receive follow remuneration assess auditor make recommendation service statutory auditor roche holding board information authority ltd auditor roche company responsibilitie audit committee include chugai article bylaw statutory auditor participate meeting audit committee millions chf auditing service performance kpmg assess base auditrelated service different element affiliate survey assurance evaluate service level country level nonstatutory audits interview roche key stakeholder tax service selfevaluation kpmg internal process service ensure compliance federal audit oversight total authority faoa audit committee guide kpmgs independence ensure limit audit fee review head group audit kpmg provide certain nonaudit service approve audit committee year furthermore permit service exceed take consideration change roche total audit fee explicitly business change financial reporting rewieve approve audit committee audit standard regulation company formal policy governing engagement statutory auditor nonaudit statutory auditor elect year service limit certain permit annual general meeting httpswwwrochecomaboutgovernancearticleofincorporationhtmcorporate governance roche auditing service provide legally require tax service include service respect compliance tax return tax advice auditrelated service include assurance service relate audit tax accounting service provide auditor necessarily provide statutory service include advice relate process auditor service legal improvement regulation training requirement include attestation service comfort letter consent consultation relationship independent proxy testaris serve independent meeting period proxy annual general meeting conclusion ordinary annual general march shareholder elect testaris meeting shareholder independent proxy period conclusion ordinary annual rule issue instruction general meeting shareholders testaris independent proxy rule electronic pay service annual general meeting participation annual general meeting accord expenditure totalling chf lay correspond invitation chf annual general meeting regulate article incorporation board director nominate testaris election independent proxy annual general information policy provide article incorporation presentation analyst investor conference corporate notice publish swiss official available internet publication gazette commerce daily newspaper available designate board director basler httpswwwrochecompublicationshtm zeitung finanz und wirtschaft lagefi temps order email neue zrcher zeitung baselwarehouseservicesrochecom fax roche report halfyear fullyear result business report publish print andor online contact address investor relation format medium event addition detail hoffmannla roche ltd investor relation firstquarter month sale figure group finance basel switzerland publish year april october tel current list publication date available fax english german internet additional information include detail specific relevant information document include contact person available internet medium release investor update httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecommediahtm httpswwwrochecominvestorshtm httpswwwrochecominvestorscontactshtmcorporate governance roche chief compliance officer compliance officer network chief compliance officer compliance compliance tool furthermore serve officer network commit ensure platform idea suggestion concern roche group code conduct consistently document comply roche group chief compliance officer serve contact addition roche establish business ethic person shareholder employee business incident report beir system enable partner customer supplier general chief compliance officer capture track public issue relate implementation monitor allege violation initial report compliance code local compliance officer group internal investigation department resolution employee party aware violation roche group code business ethic incident record system conduct bring attention group internal investigation department manager supervisor local regionallocal management receive specific compliance officer report concrete information allege violation chief compliance officer pascale schmidt roche group code conduct email pascaleschmidtrochecom certain predefine category corporate tel disclosure governance sustainability committee treat confidentially addition employee audit committee board director anonymously report irregularity complaint inform substantial violation management mother tongue speakup line case corrective action take question uncertaintie interpretation roche group code conduct chief compliance officer report general reference document employee reach counsel submit regular report line manager local compliance officer corporate governance sustainability committee chief compliance officer contact need audit committee board roche group code conduct help advice line director nonapplicabilitynegative disclosure expressly note information negative declaration provide swis contain mention non exchange corporate governance directive applicable omission construe commentary thereto httpswwwrochecomaboutgovernancecodeofconducthtm httpswwwrochecomaboutgovernancecodeofconductcomplianceofficerhtm httpswwwrochecomaboutgovernancecodeofconducthtmnoitarenumer troperremuneration report roche performance successbase transparent market competitive remuneration important factor globally operate company like roche principle roche innovative agile company performance successbase success depend substantially expertise transparent compensation structure ensure motivation performance employee compensation package competitive conviction form basis compensation policy structure individual component regularly benchmarke base relevant swiss european roche aim remunerate employee fairly international market criterion remuneration transparently line market condition guideline underlie principle enable participate appropriately subject regular outside comparison company success pursue goal provide equitable competitive performance compensation policy factor base resultsoriente compensation safeguard roche future success key element corporate culture offer employee strive balanced mix fix variable condition good compensation component gear possible contribution share corporate goal employee position management responsibility improve healthcare patient include sound sustainabilityoriente value system firstly variable component intend base integrity courage passion create additional financial incentive achieve time decentralise management corporate goal innovation approach play major role wide scope consistently high level increase value individual decisionmake respectful interaction company create stakeholder openness diversity widerange training group secondly order allow employee development opportunity attractive manager participate company business working environment unidimensional diminishment success adequate compensation measure question remuneration fall far key objective incentivise annual short bonus payment longterm securitiesbase programme roche commit fair performancebase resultsoriente compensation policy link global company like roche market employee interest competitive remuneration play key role stakeholder group compensation policy httpswwwrochecomcareersforemployeesrewardshtm sound value system httpswwwrochecomcareersforemployeeslivingourvalueshtmremuneration report roche remuneration decision process approval framework overview chairman group ceo member year remuneration committee roche group corporate executive committee board director decide remuneration present remuneration committee decide board member member group correspond compensation right corporate executive committee decision decision right reserve remuneration committee member remuneration decision process approval framework beneficiary remuneration board director bod corporate executive decision approval component chairman committee cec incl ceo roche group base payremuneration bonus stocksettle stock remuneration committee appreciation right ssar restrict stock unit rsus annual general performance share plan psp board director meeting expire plan recommendation psp remuneration committee time end decision pension remuneration committee remuneration committee track market datum bylaw roche board director salary lead global pharmaceutical article incorporation outline company major swiss company section principle govern report finding board external specific remuneration component consulting firm pricewaterhousecooper pwc assist remuneration committee roche end new award grant perform market comparison advise performance share plan psp act pwc award additional mandate recommendation remuneration roche group information remuneration committee end board committee remit power procedure director determine payment make remuneration decision find expire psp peer set abbott laboratories abbvie amgen astella astrazeneca bayer bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck novartis pfizer sanofi takeda change composition peer set compare abb credit suisse lafargeholcim nestl sonova straumann swis ubs zurich insurance change composition peer set compare httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecomaboutgovernancearticleofincorporationhtm total aggregate amount aktiengesellschaften vegv general meeting base decision submit shall vote annually bind effect general meeting approval implement approval remuneration board ordinance excessive compensation director resolve board director list jointstock company verordnung gegen corporate executive committee detail bermssige vergtungen bei brsenkotierten abbott laboratories abbvie amgen peer set astellas astrazeneca abb bayer credit suisse bristolmyers squibb lafargeholcim eli lilly nestl roche glaxosmithkline sonova johnson johnson straumann merck swiss novartis ubs pfizer zurich insurance sanofi takeda peer set market comparison company salary assessment pharma peer set major swiss company procedure submit total board retrospective approval executive remuneration shareholder total aggregate bonus amount corporate approval annual general meeting executive committee chairman board year annual general meeting agm director financial year end shareholder approve total remuneration submit retrospectively ordinary agm board director corporate executive separate bind approval committee decide board director remuneration committee board director prospective approval respectively board executive aggregate remuneration submit prospectively accord approval agm agm separate bind approval roche commit obtain separate period ordinary agm bind shareholder approval total remuneration pay board director corporate executive committee followsremuneration report roche andr hoffmann chairman remuneration committee approval total remuneration annual general meeting agm financial year financial year retrospective bonus chairman board director bod bonus financial year total cec corporate executive committee cec include ceo roche group bonus bonus financial year total prospective bod base payremuneration board director bod include chairman aggregate total remuneration agm agm base payremuneration cec corporate executive committee cec include ceo roche group base pay aggregate total remuneration agm agm ssar base pay rsus stocksettle stock appreciation right ssar indirect benefit restrict stock unit rsus indirect benefit agm agm agm remuneration component overview remuneration element exist individual target value total corporate executive committee lti corporate executive committee member enlarge corporate executive committee base pay measure january composition remuneration component year vest expiration period align longterm incentive lti change newly issue ssar rsus lti corporate executive committee unlike participant programme enlarge corporate executive member corporate executive committee committee complement choice determine mix rsus restrict stock unit rsus compose ssar fouryear ssar rsus base cliff vest corporate executive committee lti mix ssarsrsus fix base calculation vest period cliff vest expiration period base individual ssar target value total lti year year year corporate executive committee member base pay rsus measure january year year year remain participant ssar year give participant additional rsus programme offer yearly year exercise vest ssar parallel basis choice combination determine vest schedule newly issue rsus mix restrict stock unit rsus stock change threeyear cliff vest settle stock appreciation right ssar option fouryear annual vest year unlike instead ssar country corporate executive committee follow option available enlarge corporate executive committee grant rsus vest choice choice choice available participant vest schedule ssar ssar ssar ssar threeyear annual vest rsus rsus rsus align fouryear annual vest schedule new grant offer level choice empower participant engage fully total reward enable attractively design roche longterm well understand critical element incentive programme enable roche attract compensation increase value motivate retain good talent programme align company longterm success expiration period newly issue ssar extend seven year tenremuneration report roche remuneration member board remuneration component link director corporate executive committee employee performance company financial compose follow element concrete performance nonfinancial success composition chart composition align interest roche employee remuneration board director shareholder societal environmental corporate executive committee objective take account fix base salary complement lti remuneration component intend annual variable bonus shortterm incentive sustainably homogenously longterm sti perennial remuneration element orient perspective align management interest ssar rsus longterm incentive lti shareholders holders nonvoting equity security participate manager end new performance share additional incentive achieve sustainable plan psp award grant act shareholder value growth recommendation remuneration committee end board director determine payment expire psp composition remuneration board director corporate executive committee annual remuneration element description bod ceo roche group cec base pay monthly payment uarterly remuneration payment bonus annual payment year year cash block nonvoting block nonvoting equity security equity security andor share andor share pension etc perennial remuneration element stocksettle stock year appreciation right additionally ssar block nonvoting equity security exercise restrict stock year unit rsus block nonvoting equity security performance share year plan psp block nonvoting expire plan equity security psp andor share fix base salary indirect benefit employer contribution pension insurance contribution sti roche roche connect bonus remuneration tax consulting service lti component expense allowance stocksettle stock appreciation right restrict stock unit performance share plan childrens school cost foreign tax obligation variable longterm ahvivalv employer contribution social security beneficial part base pay fix rate operate profit capital charge opac base pay cash payment determine base core operating profit core earning position base salary market datum lead share nonvoting equity security ne growth global pharmaceutical company footnote constant exchange rate product development major swiss company footnote pipeline diversity employee manager reflect individual ability experience environmental goal additionally link performance time pay adjustment achievement measurable qualitative likewise link individual performance individual functional performance objective account prevail market condition competitive reason roche disclose company overall financial situation individual performance objective member corporate executive committee remuneration committee make review chairman final decision individual base pay pay chairman board director member december end report year corporate executive committee january follow report year remuneration remuneration member board committee decide bonus amount payable chairman board bonus variable member corporate executive committee bonus annually award individual respect relevant reporting year base contribution value creation business year performance aforementioned objective mean incentive strive outstanding time remuneration committee result create new business opportunity decide form bonus award bonus amount link group divisional cash payment andor block applicable core profit sale growth constant exchange nonvoting equity security andor sharesremuneration report roche remuneration committee use discretion define fouryear vest period plus value appropriately weight criterion adjustment equivalent bonus allocation sum dividend pay vest period attributable number nonvoting equity total employee security andor share individual eligible bonus roche bonus program award grant vested recipient corporate executive committee stocksettle stock appreciation right year result nonvoting ssar longterm equity security andor share remain block ssar proportion lti year corporate executive committee base individual target value total rsus serve remuneration component lti corporate executive committee member eligible roche employee base pay measure january year performance share plan psp longterm psp establish period ssar entitle holder benefit financially year base threeyear increase value roche nonvoting equity comparison total shareholder return tsr security grant date exercise peer company footnote plan date ssar grant vest key performance metric award tsr year exercise calculated threemonth move average year grant date unexercised ssar rate start end lapse compensation fair performance cycle value ssar calculate grant date trinomial model american new psp award grant option detail end performance cycle psp left ssar corporate executive committee closed december allocate individually remuneration board director discretion act committee discretion recommendation remuneration committee determine payment end total employee receive ssar restrict stock unit rsus longterm indirect benefit proportion restrict stock unit show ceo roche group rsus member corporate executive chairman respectively members committee total lti base corporate executive committee additionally individual target value total lti corporate receive indirect benefit payment pension executive committee member fund insurance roche connect payment base pay measure january year rsu foreign tax obligation tax consulting service award allocate individually corporate annual expense allowance show executive committee remuneration individual member corporate executive committee discretion committee receive payment family child education allowance school cost rsus contain right receive nonvoting equity child security andor share newly weight fixedvariable longterm remuneration component target percentage total remuneration chairman board director corporate executive committee include ceo roche group fix variable longterm variable longterm remuneration pay member corporate executive committee range fix compensation ratio variable remuneration component relative fix base pay corporate executive committee ratio variable remuneration component bonus ssar rsus relative value fix base pay lti longterm sti variable total criterion bonus ssar total lti rsus total lti individual target value minimum maximum performance criterion group objective group divisional business value development value development performance individual objective consider determined determined core profit sale growth constant exchange performance ne performance plus rate operate profit capital charge opac grant value adjustment base core operating profit core earning dividend nes share nonvoting equity security ne growth grant constant exchange rate product development pipeline diversity employee manager environmental goal split group objective individual objective weighting criterion remuneration committee discretion decision objective applicable assess consideration performance competitor macroeconomic development base exist individual target value total lti corporate executive committee member base pay measure january year detail refer follow section remuneration report finance report note roche group consolidate financial statement relate party note financial statement roche holding ltd board executive shareholding remuneration board director resolution approval director table board remuneration chairman board activity roche pay legally require employer director member board director contribution totalling chf swiss social decide remuneration committee security programme provide retirement disability discretion take account market comparison unemployment benefit ahvivalv member board director legally remuneration form cash payment require contribution separately state annually track market datum chairman board director director pay lead global pharmaceutical company footnote major swiss basic remuneration board director company footnote assist exclude chairman remain unchanged consultancy pwc previous year board exception chairman board director separately submit total aggregate director bonus form block share bonus chairman board directors severin schwan executive member general meeting financial year board member board director retrospective bind approval award share nonvoting equity security ssar maximum amount total aggregate remuneration board director period loan credit grant member ordinary general meeting board director ordinary general meeting separately table previous year capacity member chugai general meeting prospective bind approval international council cic chugai pharmaceutical ltd andr hoffmann receive honoraria amount total usd chf remuneration member board director advisory service genentech member board director scientific resource board prof richard lifton receive remuneration additional compensation receive honoraria amount total form quarterly fix cash payment usd chf prof hans clever show remuneration member board usd chf respectively list member position committee membership chairmanship detidua remuneration report roche remuneration member board director chf additional remuneration additional special basic remuneration committee memberschair remuneration total remuneration franz chairman total remuneration pay chairman board director hoffmann vicechairman brown bulcke clever duschmal march frost march hauser lifton poussot schwan high total remuneration pay severin schwan member corporate executive committee remuneration receive primary function ceo roche group reflect total remuneration corporate executive committee suessmuth dyckerhoff bell march oeri march total exception member chairmans committee chairman vicechairman board member receive chf year committee serve chf year committee chair remuneration serve vicechairman board prorate remuneration period march december prorate remuneration period january march additionally employer contribution ahvivalv totalling chf include chairman pay form remuneration detidua remuneration member board director chf additional remuneration additional special basic remuneration committee memberschair remuneration total remuneration franz chairman total remuneration pay chairman board director hoffmann vicechairman bell brown bulcke clevers march hauser lifton oeri poussot schwan high total remuneration pay severin schwan member corporate executive committee remuneration receive primary function ceo roche group reflect total remuneration corporate executive committee suessmuth dyckerhoff voser end june total exception member chairmans committee chairman vicechairman board member receive chf year committee serve chf year committee chair remuneration serve vicechairman board prorate remuneration period march december prorate remuneration period january end june additionally employer contribution ahvivalv totalling chf include chairman pay form remuneration total remuneration pay chairman form share block year payable board director march shareholder bind vote chairman christoph franz receive total ordinary annual general meeting agm remuneration show remuneration committee bonus proposal adopt chairman total remuneration contain late respect financial year total remuneration board director total remuneration pay chairman board director chf base salary cash bonus subject approval annual general meeting pension fundsinsurancesannual expense allowance include employer contribution social security beneficial part total form share block year calculation number share base price date transfer march respectively approval agm agm respectively calculation value consideration reduction value block period year reduce market value submit shareholder approval agm approve agm respectively agree reduction pension fund contribution reach age dditionally employer contribution ahvivalv chf chf pay form remuneration detidua detidua remuneration report roche total remuneration pay board board remuneration subject approval director annual general meeting calendar year member board director receive remuneration submission chairman total include bonus employer contribution aggregate bonus bind vote social security beneficial part totalling annual general meeting chf chf exclude remuneration chairman board additional employer contribution pay ahviv director include bonus award chf alv totalling chf chf form share block year show form remuneration table section total remuneration pay chairman board director remuneration pay member board director submit remuneration board director committee bonus proposal adopt late member board director franz chairman board christoph franz humer receive fee amount total respect financial year payable usd chf serve member march exclude legally require employer chugai international council cic chugai contribution ahvivalv shareholder pharmaceutical ltd bind vote ordinary annual general meeting member board director william burns receive honoraria amount total usd chf capacity member chugai international council cic chugai pharmaceutical ltd additional remuneration pay retrospective approval chairman total aggregate bonus chf proposal agm agm agm aggregate aggregate aggregate financial year financial year financial year total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv bonus award form share block year calculation number share base price date transfer march march march respectively approval agm agm agm respectively calculation value consideration reduction value block period year reduce market value submit shareholder approval agm approve agm agm respectively detidua remuneration report roche submission board total aggregate severin schwans remuneration show future remuneration bind shareholder receive function ceo vote roche group member corporate board director propose executive committee include ordinary agm approve board remuneration totalling corporate executive committee chf exclude legally total remuneration require employer contribution ahvivalv exclude bonus period end ordinary agm prospective approval board total aggregate future remuneration chf proposal agm agm agm aggregate aggregate aggregate period period period agm agm agm agm agm agm total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv exclude bonus reconciliation report exclude bonus period end remuneration shareholder approve ordinary agm remuneration member board director comparison ordinary agm ordinary agm approve board ordinary agm actual remuneration remuneration totalling amount chf exclude legally chf exclude legally require require employer contribution ahvivalv employer contribution ahvivalv exclude bonus prospectively approve total remuneration member board director comparison actual total payment chf total remuneration total remuneration total remuneration period period period agm agm agm agm agm agm maximum total remuneration approve agm actual total remuneration pay calculation end period approve limit calculation end period yes yes exclude legally require employer contribution ahvivalv exclude bonus security holding statement relate party director andr hoffmann jrg duschmal note financial statement roche member founder family hold ltd significant shareholder closely associate belong addition december contractually bind shareholder group december respectively member pool voting right end board director person closely group hold share issue associate hold roche share share detailed information group nonvoting equity security nes american find finance report note depositary receipt adrs show roche group consolidated financial table security holding security holding share nes december december nonvoting nonvoting close equity close relative equity relative security security security security share ne holding number share ne holding number number number numbertype type number number numbertype type board director franz hoffmann brown bulcke clevers duschmal frost hauser ne nes lifton adr adrs poussot schwan security holding security holding corporate executive committee corporate executive committee suessmuth dyckerhoff total ne adr ne adr applicable share hold shareholder group pool voting right list jointly hold close relative oche adr american depositary receipt list otcqx httpswwwotcmarketscomstockrhhbyquote international premier symbol rhhby isin trade usd adr represent underlying nesremuneration report roche remuneration corporate executive committee resolution approval remuneration member remuneration member corporate corporate executive committee executive committee decide general provision assign authority remuneration committee discretion taking decision corporate executive committee account market comparison remuneration remuneration committee board director outline previous year board remuneration decision process approval director separately submit total aggregate framework bonus corporate executive committee general meeting financial year member corporate executive retrospective bind approval committee receive remuneration work show remuneration maximum amount total aggregate ceo roche group severin schwan remuneration corporate executive committee explain detail period ordinary general meeting ordinary general meeting payment gottlieb keller retire table previous year corporate executive committee general meeting prospective bind approval roche end march include aggregate total remuneration corporate executive committee high total remuneration pay high total remuneration pay member severin schwan member corporate executive committee corporate executive committee include total pay corporate severin schwan executive member board executive committee total remuneration director receive remuneration primary pay member corporate executive function ceo roche group reflect committee high total remuneration pay severin schwan member corporate executive committee chf base salary bonus subject approval total aggregate bonus corporate executive committee annual general meeting ssar rsus roche connect pension fundsinsurance payment incl expense allowancefor tax consulting service total light overall economic impact corona pandemic severin schwan waive chf contractual base salary detailed calculation remuneration annual report share block year calculation number share base share price date transfer march approval agm sars number grant value accord trinomial model american option chf trinomial model american option value describe stocksettle stock appreciation right ssar member corporate executive committee ssar block year exercise whilst exercise result ne automatically block additional year calculation value nonvoting equity security consideration reduction value additional block period year reduce market value ssar number grant value accord trinomial model american option chf trinomial model american option value describe stocksettle stock appreciation right ssar member corporate executive committee ssar block year exercise whilst exercise result ne automatically block additional year calculation value nonvoting equity security consideration reduction value additional block period year reduce market value calculation rsus value number rsus multiply grant value chf ne closing price grant date march rsu calculation rsus value number rsus multiply grant value chf ne closing price grant date march rsu include annual expense allowance chf payment tax consulting service chf chf family child education allowance chf chf additionally employer contribution ahvivalv chf chf pay form remuneration calculation value nonvoting equity securitiesshare consideration reduction value block period year reduce market value include employer contribution social security beneficial part detidua base pay member corporate executive committee base pay chf anderson hippe schinecker wilbur total base pay gottlieb keller retirement bonus chf propose roche end march include include aggregated total remuneration aggregate total remuneration corporate executive committee corporate executive committee total aggregate bonus bring forward bind vote annual bonus member general meeting corporate executive committee remuneration committee board severin schwan member director determine corporate executive corporate executive committee receive committee member bonus base bonus cash payment severin performance agree objective schwan receive bonus form roche remuneration committee use discretion share block year appropriately weight criterion bonus payment march bonus allocation gottlieb keller bonus chf subject approval total aggregate bonus corporate executive committee annual general meeting anderson hippe schinecker wilbur total detidua detidua remuneration report roche stocksettle stock appreciation right total lti corporate executive committee ssar member corporate member base pay measured executive committee january year ssar corporate executive committee allocate individually remuneration fair value ssar calculate grant committee discretion ssar show date trinomial model american ssar table entitle holder option trinomial model effective method benefit financially increase value valuation american option consider roche nonvoting equity security nes possibility exercise option time prior grant date exercise date strike price maturity call american option compare ssar term multiyear plan european option allow exercise closing price roche ne grant date maturity date ssar vest previously grant ssar year grant date vest number ssar strike price expiry ssar exercise convert ne date grant value ssar show previously grant ssar seven year ssar table grant date unexercised ssar lapse number ssar calculate time issue compensation enter value table ssar proportion lti corporate executive committee base ssar grant gottlieb exist individual target value keller restrict stock unit rsus individually corporate executive committee member corporate executive remuneration committee discretion committee proportion restrict stock unit rsus contain right receive nonvoting equity rsus member corporate executive security andor share newly committee compose total lti define fouryear vest period plus value base exist individual target value adjustment equivalent total lti corporate executive committee sum dividend pay vest period member base pay measure attributable number nonvoting equity january year rsu award allocate security andor share individual information trinomial model american option refer boyle phelim lattice framework option price state variable journal financial quantitative analysis volume issue mar httpswwwrochecomdamjcraaacbfa bcbeacentrinomialmodelpdf detidua stocksettle stock appreciation right ssar grant value grant value number ssar chf value chf number ssar chf value chf anderson hippe schinecker wilbur total price chf expiry date price chf expiry date performance share plan psp committee determine payment end member corporate executive committee psp establish period provision plan number year base threeyear nonvoting equity security nes share comparison total shareholder return tsr reserve participant cycle peer company footnote plan number security actually award depend key performance metric award tsr extent investment roche calculate threemonth move average security share ne outperform average rate start end return investment security issue set performance cycle peer company footnote comparison base security market price dividend new psp award grant yield total shareholder return tsr end reduce effect shortterm market fluctuation performance cycle psp leave security price average month close december october december prior start board director discretion act performance cycle month recommendation remuneration october december end cycle detidua remuneration report roche award grant vested gottlieb keller receive rsu award recipient corporate executive committee year result nonvoting equity security andor share remain block year restrict stock unit rsus value grant value grant number chf value chf number chf value chf anderson hippe schinecker wilbur total calculation value consideration reduction value additional block period year reduce market value calculation value consideration reduction value additional block period year reduce market value detidua roche security perform well average indirect benefit member peer set board director elect corporate executive committee increase nes share award maximum employer contribution social award double originallevel reserve target security scheme pension plan groupwide number ne share accord psp plus employee stock purchase plan roche connect value adjustment equivalent respect member corporate executive sum dividend pay vest committee show indirect benefit period attributable number nonvoting employer contribution table equity security share individual table award grant require roche security perform well roche connect voluntary stock purchase peer set event investment plan offer employee opportunity buy roche security underperform average roche nonvoting equity security ne return deliver peer company few equal annual salary ne share award discount ne purchase plan subject hold period year end psp cycle base switzerland threemonth average distribute dividend total chf billion chf billion addition member corporate executive chf billion chf billion committee receive annual expense allowance accord term plan participant member payment foreign tax receive originally target ne obligation tax consulting service show award end psp cycle table ne originally target ne incl ne group ceo outline page payment employer contribution indirect annual report take benefit gottlieb keller retirement account retire member corporate roche end march include executive committee award aggregate total remuneration corporate executive committee bill anderson thomas schinecker participate psp programme indirect benefit employer contribution chf payment payment annual taxtax annual taxtax pension fund expense roche consulting pension fund expense roche consulting insurance allowance connect service insurance allowance connect service anderson hippe schinecker wilbur total include employer contribution social security beneficial partsdetidua detidua detidua remuneration report roche remuneration loan member contribution social security beneficial part corporate executive committee payment gottlieb keller meet legal contractual obligation retirement end march totalling roche pay total chf individual chf exclude member corporate executive committee additional employer contribution pay ahviv family child education allowance alv totalling chf chf children schooling cost form remuneration aforementione additional payment additional remuneration include total remuneration member abovementione payment pay current corporate executive committee member corporate executive committee loan credit grant member corporate executive committee executive remuneration subject approval annual general meeting maximum regular period notice member corporate executive committee month submission executive total aggregate changeofcontrol clause bonus bind vote annual employment contract general meeting board director propose award remuneration member member corporate executive committee corporate executive committee bonus severin schwan form roche additional remuneration share block year abovementione payment pay member corporate executive committee member corporate executive committee cash payment totalling chf respect financial total remuneration pay member year chf exclude legally corporate executive committee require employer contribution ahvivalv calendar year member submit propose total corporate executive committee receive ordinary annual general meeting agm remuneration include bonus employer bind vote retrospective approval member executive committee total aggregate bonus chf proposal agm agm agm aggregate aggregate aggregate financial year financial year financial year total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv submission executive total future incentive ssar calculate grant value aggregate remuneration bind consider reduction value shareholder vote block period applicable rsus board director propose calculated time reservation nonvoting ordinary agm approve remuneration equity security share consider corporate executive committee totalling reduction value blocking period chf exclude legally contribution pension benefit exclude legally require employer contribution ahvivalv require employer contribution ahvivalv exclude bonus period end contribution expense payment ordinary agm foreign tax obligation tax consulting service roche connect executive total future aggregate remuneration compose base pay longterm prospective approval member executive committee total future aggregate remuneration chf proposal agm agm agm aggregate aggregate aggregate period period period agm agm agm agm agm agm total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv exclude bonus reconciliation report exclude bonus period end remuneration shareholder ordinary agm prospectively approve remuneration member corporate executive comparison ordinary agm committee ordinary agm remuneration amount ordinary agm approve remuneration chf exclude legally require corporate executive committee totalling employer contribution ahvivalv chf exclude legally exclude bonus psp assumption maximum require employer contribution ahvivalv valueremuneration report roche prospectively approve total remuneration member executive committee comparison actual total remuneration effect chf period period period agm agm agm agm agm agm maximum total remuneration prospectively approve agm total remuneration calculate end calculation end corresponding agmagm period period agm agm actual total remuneration realise corresponding agmagm period base calculate calculate actual calculate retrospectively end period end psp cycle end correspond psp cycleas calculation end agm agm grant value rsus period agm agm approve limit calculation end period yes yes additional pay new member corporate executive committee approval agm approved total exclude legally require employer contribution ahvivalv exclude bonus include assumption maximum possible award sharesnonvote equity security correspond psp cycle esulting award originally target ne psp cycle clawback activity lead disciplinary action addition applicable statutory provision repeat willful failure perform duty roche longterm incentive plan include reasonably assign roche option partially reclaim distribute compensation violation law public regulation result special circumstance clawback commission crime gross negligence willful misconduct employee voluntarily serve notice employment termination employment ssar engage conduct bring disgrace disrepute rsus unvested date roche andor subsidiary termination employment lapse immediately violation roche directive guideline compensation relate business conduct termination employment result accord regulation psp programme misconduct ssar rsus grant originally target award ne outstanding vest unvested shall lapse share shall lapse compensation immediately compensation accord notice termination employment give ssar plan rule misconduct reason redundancy disability participant include inter alia retirement guideline security holding holding long serve board director decide corporate executive committee exception ceo roche group members bill anderson thomas schinecker corporate executive committee acquire join corporate executive committee share andor nes equivalent annual base fulfil requirement end salary ceo roche group equivalent member corporate executive annual base salarie annual base committee fulfil requirement salary respectively end retain type security value acquire ceo roche group share andor nes annual base salary member corporate executive committee share andor nes annual base salary security holding associate held security show december december follow table share nonvoting equity respectively member corporate security ne ssar restrict stock executive committee person closely unit rsus share nonvoting equity security nes december december close relative close relative share ne security holding share ne security holding number number numbertype number number numbertype corporate executive committee share ne share nes schwan anderson hippe schinecker wilbur total remuneration report roche ssar number ssar hold december corporate executive committee schwan anderson hippe schinecker wilbur total price chf market price ne december chf expiry date grant value ssar chf trinomial model american option value accord correspond annual report restrict stock unit rsus number rsus hold december corporate executive committee schwan anderson hippe schinecker wilbur total grant value rsu chf chf chf ne closing price grant date ne closing price grant date ne closing price grant date march march march applicablestatutory auditor report roche general meeting roche holding ltd basel audit accompany assurance remuneration remuneration report roche holding ltd report complie swiss law article year end december ordinance audit limited information accord article ordinance audit involve perform procedure excessive compensation list jointstock obtain audit evidence disclosure company ordinance contain remuneration report regard section mark audit grey line compensation loan credit accordance include respective footnote page article ordinance remuneration report procedure select depend auditor judgement include assessment risk responsibility board director material misstatement remuneration board director responsible report fraud error audit preparation overall fair presentation include evaluate reasonableness remuneration report accordance swiss method apply value component law ordinance board director remuneration assess overall responsible design remuneration presentation remuneration report system define individual remuneration package believe audit evidence obtain sufficient appropriate provide auditor responsibility basis opinion responsibility express opinion accompany remuneration report opinion conduct audit accordance swiss opinion remuneration report auditing standard standard require year end december roche hold comply ethical requirement ltd complies swiss law article plan perform audit obtain reasonable ordinance kpmg mark baillache marc ziegler license audit expert license audit expert auditor charge basel february kpmg viaduktstrasse box basel kpmg subsidiary kpmg holding member kpmg network independent firm affiliate kpmg international cooperative kpmg international swiss legal entity right reserve independent limited assurance report nonfinancial report corporate governance sustainability committee roche holding basel engage perform assurance figure roche group level relation procedure provide assurance aspect payment donation disclose nonfinancial report roche report hold basel consolidated subsidiary management reporting process roche include annual report respect payment donation report contribution key figure relate control environment relation datum scope subject matter aggregation key figure assurance engagement relate limited level assurance focus datum information criterion year end december disclose management reporting process respect report roche nonfinancial report key figure prepare roche base policy carry work datum report procedure set forth follow prior reporting period respect roche group guideline grant donation projection target sponsorship gsd data collection process disclose website follow specify datum information roche group internal nonfinancial reporting publish report scope guideline base responsible care limited assurance engagement health safety environmental protection materiality determination process roche reporting guideline publish european group level according requirement chemical industry council cefic gri standard disclose gri standard publish october report global reporting initiative gri design sustainability risk roche group internal corporate reporting opportunity determination process base manual sustainability report guidance roche group level activity disclose economic performance issue march paragraph risk management roche materiality determination process report group level base gri standard safety security health environmental publish october global reporting protection key figure include initiative gri greenhouse gas emission scope define guideline payment scope result business flight donation contribution key figure table graphs sustainability risk opportunity internally report gather collate aggregate pricewaterhousecoopers birchstrasse postfach zurich telephone telefax wwwpwcch pricewaterhousecoopers member global pricewaterhousecooper network firm separate independent legal entityindependent limited assurance report roche inherent limitation requirement professional standard accuracy completeness nonfinancial applicable legal regulatory requirement indicator subject inherent limitation give nature method determine responsibility calculate estimate datum ghg responsibility perform limited assurance quantification subject inherent uncertainty engagement express conclusion incomplete scientific knowledge aspect nonfinancial reporting determine emission factor value roche plan perform procedure need combine emission different gas accordance international standard assurance report read assurance engagement isae revise connection roche guideline definition assurance engagement audits procedure thirdparty review historical financial information guideline present select non respect greenhouse gas emission financial reporting performance international standard assurance engagement isae assurance engagement roche responsibility greenhouse gas statement issue roche corporate governance international auditing assurance standard sustainability committee responsible board standard require plan subject matter criterion include perform procedure obtain limited assurance selection preparation presentation specify nonfinancial information select information accordance prepare material aspect accordance criterion responsibility include design roche policy procedure implementation maintenance relate internal management reporting process control relevant reporting process free relate control environment relation material misstatement fraud datum aggregation work design form error appropriate basis reporting follow gri standard nonfinancial performance independence quality control roche focus independent roche hold accordance international code limited assurance engagement substantially ethic professional accountant include scope reasonable assurance international independence standard issue engagement relation risk assessment international ethic standard board procedure include understand internal accountant iesba code fulfil control procedure perform response ethical responsibility accordance assess risk consequently nature iesba code timing extent procedure gather sufficient appropriate evidence deliberately pricewaterhousecooper apply international limited relative reasonable assurance standard quality control accordingly engagement assurance maintain comprehensive system quality obtain limited assurance engagement control include document policy reasonable assurance engagement procedure compliance ethical procedure select depend assurance requirement address soundness practitioner judgement identification process determination impact stakeholder peer competition review summary work perform integration relevant regulatory requirement assurance procedure include integration key organisational value follow work objective report prioritisation material review application roche group aspect guideline inspect integration sustainability risk review application roche group opportunitie group risk management nonfinancial reporting contribution process adherence internal guideline guideline site visit management inquiry assessment process datum remotely visit select site roche consolidation pharmaceutical diagnostic division review management nonfinancial usa switzerland china indonesia report process payment selection base quantitative donation contribution key figure qualitative criterion assess aggregation process datum interview personnel responsible internal roche group level nonfinancial report datum collection site visit roche group level conduct work datum determine understand application outline subject matter define roche nonfinancial contribution believe evidence guideline obtain sufficient appropriate provide assessment key figure basis assurance conclusion perform test sample basis evidence support select payment limit assurance conclusion donation contribution roche accident base work perform come rate energy consumption coequivalent attention cause believe emission water usage discharge donation material aspect political party switzerland concern roche materiality determination process completeness accuracy adequacy group level disclose adhere consistency principle guide factor soundness review documentation analysis relevant stakeholder determination peer review relevance policy principle regulatory environment integration key review relevant documentation sample organisational value objective define basis include roche group nonfinancial gri standard report policy management report design sustainability risk structure documentation opportunity determination process group review principle roche level disclose function design materiality process provide definition select key figure mention scope development adherence gris disclose nonfinancial report environmental social economic reporting pricewaterhousecoopers birchstrasse postfach zurich telephone telefax wwwpwcch pricewaterhousecoopers member global pricewaterhousecooper network firm separate independent legal entityindependent limited assurance report roche roche annual report state accordance report criterion management reporting process collect aggregate payment donation contribution key figure control environment relation datum aggregation work design pricewaterhousecoopers christophe bourgoin helene baron zurich february publish hoffmannla roche ltd group communications basel switzerland tel wwwrochecom key date orderdownload publication internet rochecompublication annual general meeting email baselwarehouseservicesrochecom march fax firstquarter sale medium relation april tel email mediarelationsrochecom halfyear results july investor relation tel ninemonth sale email investorrelationsrochecom october corporate sustainability committee tel email corporatesustainabilityrochecomimprint roche cautionary statement forward trademark legally protect look statement annual report contain certain forwardlooke link thirdparty page provide statement forwardlooke statement convenience express opinion identify word believe expect content thirdparty page expressly anticipate project intend seek disclaim liability thirdparty information estimate future similar expression use thereof discussion thing strategy goal plan intention factor cause roche annual report publish german actual result differ materially future english reflect forwardlooke statement contain annual report pricing reporting consist actual annual report product initiative competitor legislative finance report contain regulatory development economic annual financial statement consolidate condition delay inability obtain financial statement regard content regulatory approval bring product market management report article fluctuation currency exchange rate incorporation consist aforementioned general financial market condition uncertainty report exception remuneration discovery development marketing new report product new use exist product include limitation negative result clinical trial print nonchlorine bleach fsccertified research project unexpected effect paper pipeline market product increase government pricing pressure interruption production loss inability obtain adequate protection intellectual property right litigation loss key executive employee adverse publicity news coverage statement earning share growth profit forecast interpret mean roche earning earning share subsequent period necessarily match exceed historical publish earning earning share rocherehtegotregnort hoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom